

(Convenience Translation into English from the  
Original Previously Issued in Portuguese)

# **Oncoclínicas do Brasil Serviços Médicos S.A.**

Individual and Consolidated Interim  
Financial Information for the Quarters  
Ended September 30, 2021 and 2020 and  
Report on Review of Interim Financial Information

Deloitte Touche Tohmatsu Auditores Independentes Ltda.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Shareholders, Directors and Management of  
Oncoclínicas do Brasil Serviços Médicos S.A.

### **Introduction**

We have reviewed the accompanying individual and consolidated interim financial information of Oncoclínicas do Brasil Serviços Médicos S.A. ("Company"), included in the Interim Financial Information Form (ITR) for the quarters ended September 30, 2021 and 2020, which comprises the individual and consolidated balance sheets as at September 30, 2021 and 2020 and the related individual and consolidated statements of profit and loss and of comprehensive income for the three- and nine-month periods then ended, and of changes in equity and of cash flows for the nine-month periods then ended, including the explanatory notes.

Management is responsible for the preparation of this individual and consolidated interim financial information in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - IASB, as well as for the presentation of such information in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of Interim Financial Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

### **Scope of review**

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion on the individual and consolidated interim financial information**

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the ITR referred to above was not prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of ITR, and presented in accordance with the standards issued by the CVM.


## Other matters

### *Statements of value added*

The individual and consolidated interim financial information referred to above includes the statements of value added (DVA) for the nine-month periods ended September 30, 2021 and 2020, prepared under the responsibility of the Company's Management and presented as supplemental information for international standard IAS 34 purposes. These statements were subject to the review procedures performed together with the review of the Interim Financial Information (ITR) to reach a conclusion on whether they are reconciled with the interim financial information and the accounting records, as applicable, and if their form and content are consistent with the criteria set forth in technical pronouncement CPC 09 - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not prepared, in all material respects, in accordance with the criteria defined in such standard and consistently with the individual and consolidated interim financial information taken as a whole.

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

São Paulo, November 12, 2021

  
DELOITTE TOUCHE TOHMATSU  
Auditores Independentes Ltda.

  
Daniel de Carvalho Primo  
Engagement Partner

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

BALANCE SHEETS AS AT SEPTEMBER 30, 2021 AND DECEMBER 31, 2020  
(In thousands of Brazilian reais - R\$)

ASSETS	Note	Parent		Consolidated		LIABILITIES AND EQUITY	Note	Parent		Consolidated	
		09/30/2021	12/31/2020	09/30/2020	12/31/2020			09/30/2021	12/31/2020	09/30/2020	12/31/2020
			(Restated)		(Restated)			(Restated)		(Restated)	
<b>CURRENT ASSETS</b>						<b>CURRENT LIABILITIES</b>					
Cash and cash equivalents	5	1.307.300	82.553	1.773.521	740.829	Trade payables	15	35.132	46.594	373.607	345.801
Securities and financial assets	6	-	46.206	-	46.206	Borrowings and financing	16	107.352	229.613	299.513	241.876
Derivative financial instruments	6.1	-	2.549	-	2.549	Derivative financial instruments	6.1	-	-	3.158	-
Trade receivables	7	33.911	25.004	645.284	496.690	Payroll and related taxes	17	26.358	25.246	80.330	65.286
Inventories	8	11.885	7.820	55.454	37.067	Taxes payable	18	8.771	9.885	82.005	85.442
Recoverable taxes	9	20.029	13.128	100.978	79.518	Income tax and social contribution payable		-	-	37.816	27.593
Dividends receivable	29.2	2.151	2.347	-	-	Payables for acquisitions	19	1.150	2.238	152.984	109.629
Other assets	10	15.233	11.188	64.041	24.469	Dividends payable	29.5	-	-	17.661	18.526
Total current assets		1.390.509	190.795	2.639.278	1.427.328	Leases	14.2	4.566	4.227	25.860	30.500
						Other liabilities	20	17.764	20.255	34.073	96.640
						Total current liabilities		201.093	338.058	1.107.007	1.021.293
<b>NONCURRENT ASSETS</b>						<b>NONCURRENT LIABILITIES</b>					
Long-term assets						Borrowings and financing	16	240.026	324.594	1.030.834	1.157.280
Securities and financial assets	6	489	350	33.659	32.795	Derivative financial instruments	6.1	-	-	2.971	-
Escrow deposits	21	7.931	7.689	11.242	10.986	Payroll and related taxes	17	208.000	140.911	208.000	140.911
Deferred income tax and social contribution	27.c	639	639	43.479	32.782	Taxes payable	18	-	-	3.742	3.977
Related parties	29.1	82.534	63.183	28.317	18.630	- Deferred income tax and social contribution		-	-	1.064	1.558
Advances for future capital increase	29.3	180.381	122.056	-	-	Provisions for tax, labor and civil risks	21	1.054	652	36.038	20.066
Other assets	10	19.815	13.849	85.203	48.176	Payables for acquisitions	19	37.756	25.554	300.211	95.675
						Related parties	29.4	2.912	59.091	568	6.411
Investments in subsidiaries	11	631.931	765.766	-	-	Advances for future capital increase	29.6	-	-	4.928	8.476
Property and equipment	12	64.270	65.022	404.307	389.215	Leases	14.2	19.752	22.345	213.478	202.081
Intangible assets	13	66.177	71.398	1.501.827	1.208.037	Other liabilities	20	21.895	12.464	40.122	49.672
Right of use	14.1	21.991	24.693	222.990	220.620	Total noncurrent liabilities		531.395	585.611	1.841.956	1.686.107
Total noncurrent assets		1.076.158	1.134.645	2.331.024	1.961.241						
						<b>EQUITY</b>	22				
						Capital		2.207.134	416.066	2.207.134	416.066
						Expenses on public offering of shares		(103.999)	-	(103.999)	-
						Capital reserve		466.746	466.746	466.746	466.746
						Treasury shares		(28.436)	-	(28.436)	-
						Valuation adjustments to equity		12.902	11.997	12.902	11.997
						Transactions between shareholders		(470.124)	(205.186)	(470.124)	(205.186)
						Accumulated losses		(350.044)	(287.852)	(350.044)	(287.852)
						Equity attributed to owners of the Company		1.734.179	401.771	1.734.179	401.771
						Noncontrolling interests		-	-	287.160	279.398
						Total equity		1.734.179	401.771	2.021.339	681.169
<b>TOTAL ASSETS</b>		<b>2.466.667</b>	<b>1.325.440</b>	<b>4.970.302</b>	<b>3.388.569</b>	<b>TOTAL LIABILITIES AND EQUITY</b>		<b>2.466.667</b>	<b>1.325.440</b>	<b>4.970.302</b>	<b>3.388.569</b>

The accompanying notes are an integral part of this interim financial information.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF PROFIT AND LOSS  
FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020  
(In thousands of Brazilian reais - R\$, except earnings (loss) per share)

	Note	Parent				Consolidated			
		01/01/2021 to	01/01/2020 to	07/01/2021 to	07/01/2020 to	01/01/2021 to	01/01/2020 to	07/01/2021 to	07/01/2020 to
		09/30/2021	09/30/2020	09/30/2021	09/30/2020	09/30/2021	09/30/2020	09/30/2021	09/30/2020
NET REVENUE	23	136.197	122.176	41.096	41.339	1.934.187	1.460.872	679.420	524.858
Cost of services	24	(91.238)	(88.790)	(31.108)	(30.578)	(1.331.008)	(1.013.633)	(460.520)	(356.661)
GROSS PROFIT		<u>44.959</u>	<u>33.386</u>	<u>9.988</u>	<u>10.761</u>	<u>603.179</u>	<u>447.239</u>	<u>218.900</u>	<u>168.197</u>
OPERATING INCOME (EXPENSES)									
General and administrative expenses	24	(105.527)	(63.481)	117.599	(11.392)	(493.518)	(354.740)	(18.408)	(112.286)
Other operating income (expenses), net	24	654	3.270	256	933	(5.564)	(6.316)	(4.130)	(828)
Share of profit (loss) of subsidiaries	11	16.180	31.802	19.474	22.188	-	-	-	-
OPERATING PROFIT (LOSS) BEFORE FINANCE INCOME (COSTS)		<u>(43.734)</u>	<u>4.977</u>	<u>147.317</u>	<u>22.490</u>	<u>104.097</u>	<u>86.183</u>	<u>196.362</u>	<u>55.083</u>
FINANCE INCOME (COSTS)									
Finance income	25	24.344	15.814	11.656	6.912	36.357	15.142	18.118	7.804
Finance costs	25	(42.802)	(38.102)	(13.796)	(15.357)	(128.728)	(59.714)	(46.707)	(22.753)
		<u>(18.458)</u>	<u>(22.288)</u>	<u>(2.140)</u>	<u>(8.445)</u>	<u>(92.371)</u>	<u>(44.572)</u>	<u>(28.589)</u>	<u>(14.949)</u>
OPERATING PROFIT (LOSS) BEFORE INCOME TAX AND SOCIAL CONTRIBUTION		<u>(62.192)</u>	<u>(17.311)</u>	<u>145.177</u>	<u>14.045</u>	<u>11.726</u>	<u>41.611</u>	<u>167.773</u>	<u>40.134</u>
INCOME TAX AND SOCIAL CONTRIBUTION									
Current	27	-	-	-	-	(62.633)	(52.080)	(19.493)	(17.711)
Deferred	27	-	306	-	24	5.761	8.780	2.508	(69)
PROFIT (LOSS) FOR THE PERIOD		<u>(62.192)</u>	<u>(17.005)</u>	<u>145.177</u>	<u>14.069</u>	<u>(45.146)</u>	<u>(1.689)</u>	<u>150.788</u>	<u>22.354</u>
ATTRIBUTABLE TO									
Owners of the Company						(62.192)	(17.005)	145.177	14.069
Noncontrolling interests						<u>17.046</u>	<u>15.316</u>	<u>5.611</u>	<u>8.285</u>
						<u>(45.146)</u>	<u>(1.689)</u>	<u>150.788</u>	<u>22.354</u>
EARNINGS (LOSS) PER SHARE									
Basic (cents per share - in R\$)	26	<u>(0,1511)</u>	<u>(0,0423)</u>	<u>0,3614</u>	<u>0,0351</u>				
Diluted (cents per share - in R\$)	26	<u>(0,1511)</u>	<u>(0,0423)</u>	<u>0,3614</u>	<u>0,0351</u>				

The accompanying notes are an integral part of this interim financial information.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020  
(In thousands of Brazilian reais - R\$)

	Parent				Consolidated			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
PROFIT (LOSS) FOR THE PERIOD	(62.192)	(17.005)	145.177	14.069	(45.146)	(1.689)	150.788	22.354
Items that may be subsequently reclassified to the statement of profit and loss:								
Exchange rate changes on the translation of foreign transactions	905	16.064	3.161	1.364	905	16.064	3.161	1.364
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>(61.287)</b>	<b>(941)</b>	<b>148.338</b>	<b>15.433</b>	<b>(44.241)</b>	<b>14.375</b>	<b>153.949</b>	<b>23.718</b>
ATTRIBUTABLE TO								
Owners of the Company	-	-	-	-	(61.287)	(941)	148.338	15.433
Noncontrolling interests	-	-	-	-	17.046	15.316	5.611	8.285
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(44.241)</b>	<b>14.375</b>	<b>153.949</b>	<b>23.718</b>

The accompanying notes are an integral part of this interim financial information

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF CHANGES IN EQUITY (PARENT AND CONSOLIDATED)  
FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020  
(In thousands of Brazilian reais - R\$)

	Note	Attributable to owners of the Company									Total equity
		Capital		Expenses on public offering of shares	Capital reserve	Valuation adjustments to equity	Transactions between shareholders	Accumulated losses	Attributable to owners of the Company	Noncontrolling interests	
BALANCES AS AT DECEMBER 31, 2019		409.581	(9.590)	-	466.746	130	(180.003)	(130.165)	556.699	99.673	656.372
Profit (loss) for the period		-	-	-	-	-	-	(17.005)	(17.005)	15.316	(1.689)
Dividends paid	22.b)	-	-	-	-	-	-	-	-	(10.618)	(10.618)
Capital payment	22.c)	-	-	-	-	-	-	-	-	180.861	180.861
Capital decrease	22.c)	-	-	-	-	-	-	-	-	(1.919)	(1.919)
Purchase and sale of equity interest from noncontrolling shareholders	22.c)	-	-	-	-	-	(10.545)	-	(10.545)	10.406	(139)
Exchange rate changes on the translation of foreign transactions		-	-	-	-	16.064	-	-	16.064	-	16.064
Capital transactions	22.c)	-	-	-	-	-	7.098	-	7.098	2.203	9.301
BALANCES AS AT SEPTEMBER 30, 2020		<u>409.581</u>	<u>(9.590)</u>	<u>-</u>	<u>466.746</u>	<u>16.194</u>	<u>(183.450)</u>	<u>(147.170)</u>	<u>552.311</u>	<u>295.922</u>	<u>848.233</u>
BALANCES AS AT DECEMBER 31, 2020		425.656	(9.590)	-	466.746	11.997	(205.186)	(289.784)	399.839	277.467	677.306
Effects of final allocation of business combination	4	-	-	-	-	-	-	1.932	1.932	1.931	3.863
BALANCES AS AT JANUARY 1, 2021 (Restated)		425.656	(9.590)	-	466.746	11.997	(205.186)	(287.852)	401.771	279.398	681.169
Profit (loss) for the period		-	-	-	-	-	-	(62.192)	(62.192)	17.046	(45.146)
Capital payment	22.a)	1.781.478	9.590	-	-	-	-	-	1.791.068	30.129	1.821.197
Capital decrease		-	-	-	-	-	-	-	-	(400)	(400)
Treasury shares	22.a)	-	-	-	(28.436)	-	-	-	(28.436)	-	(28.436)
Expenses on public offering of shares	22.a)	-	-	(103.999)	-	-	-	-	(103.999)	-	(103.999)
Exchange rate changes on the translation of foreign transactions	22.c)	-	-	-	-	905	-	-	905	-	905
Dividends paid	22.b)	-	-	-	-	-	-	-	-	(5.795)	(5.795)
Acquisition of additional equity interest from noncontrolling shareholders	22.c)	-	-	-	-	-	(268.718)	-	(268.718)	(35.997)	(304.715)
Transactions between shareholders	22.c)	-	-	-	-	-	3.780	-	3.780	2.779	6.559
BALANCES AS AT SEPTEMBER 30, 2021		<u>2.207.134</u>	<u>-</u>	<u>(103.999)</u>	<u>438.310</u>	<u>12.902</u>	<u>(470.124)</u>	<u>(350.044)</u>	<u>1.734.179</u>	<u>287.160</u>	<u>2.021.339</u>

The accompanying notes are an integral part of this interim financial information.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF CASH FLOWS  
FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020  
(In thousands of Brazilian reais - R\$)

	Note	Parent		Consolidated	
		09/30/2021	09/30/2020	09/30/2021	09/30/2020
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>					
Loss for the period		(62.192)	(17.005)	(45.146)	(1.689)
Adjustments to reconcile loss for the period to net cash generated by operating activities:					
Depreciation and amortization	24	18.907	12.737	91.069	72.937
Allowance for expected credit losses and disallowances	23	(7.993)	5.577	45.353	45.228
Share of profit (loss) of subsidiaries	11	(16.180)	(31.802)	-	-
Income on securities		(131)	(885)	(622)	(588)
Interest on borrowings, financing and debentures	25	24.811	29.547	72.380	31.168
Interest on leases	25	1.542	1.348	12.872	6.948
Interest related to related parties and acquisitions		4.525	(7.532)	20.415	5.206
Accrued Phantom Shares	24	67.089	380	67.089	380
Foreign exchange fluctuation		152	-	285	2.113
Marked-to-market - Swap		-	(1.744)	393	(1.744)
Deferred income tax and social contribution	27	-	(306)	(5.761)	(8.780)
Derecognition of property and equipment and intangible assets	12 and 13	173	-	440	255
Provisions (reversals) for tax, labor and civil risks	21	404	(174)	2.722	(845)
		<u>31.107</u>	<u>(9.859)</u>	<u>261.489</u>	<u>150.589</u>
Changes in operating assets and liabilities:					
Trade receivables	31	(914)	(3.941)	(196.124)	(113.550)
Inventories		(4.065)	(7.054)	(15.139)	(13.506)
Recoverable taxes		(6.901)	1.242	(2.111)	(3.376)
Escrow deposits		(242)	(10)	(256)	(14)
Other assets		(6.002)	(7.235)	(4.570)	(6.895)
Trade payables		(11.462)	7.300	16.113	49.213
Taxes payable	31	(1.114)	1.180	16.365	27.981
Payroll and related taxes		1.112	5.121	12.996	25.469
Other liabilities		(11.610)	3.999	(12.310)	57.804
Net cash (generated by) used in operating activities		(41.198)	602	(185.036)	23.126
Interest paid, borrowings, financing, debentures, leases and acquisitions	14, 16 and 19	(27.427)	(30.404)	(83.502)	(37.279)
Income tax and social contribution paid		-	-	(27.954)	(13.185)
Net cash generated by (used in) operating activities		<u>(37.518)</u>	<u>(39.661)</u>	<u>(35.003)</u>	<u>123.251</u>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>					
Payment of business acquisitions, net of cash acquired	4	-	(3.729)	(120.632)	(25.303)
Acquisition of property and equipment and intangible assets	31	(27.596)	(24.955)	(78.078)	(117.802)
Advance of acquisition and partnership agreements	10 b) - e)	-	-	(53.500)	-
Securities		46.198	(45.888)	46.075	(88.521)
Dividends received		19.302	47.157	-	-
Advance for future capital increase	31	(137.687)	(87.848)	-	-
Due to related parties		(11.415)	(112.319)	(3.429)	(691)
Net cash used in investing activities		<u>(111.198)</u>	<u>(227.582)</u>	<u>(209.564)</u>	<u>(232.317)</u>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>					
Borrowings and financing	16	18.060	345.840	173.917	646.911
Repayment of borrowings and financing	16	(223.821)	(217.643)	(247.038)	(219.270)
SWAP settlement		3.828	-	3.828	-
Payment of acquisitions	19	(9.820)	(10.963)	(197.236)	(20.622)
Payment of redemption of shares		-	-	(75.751)	(50.000)
Dividends paid		-	-	(5.795)	(13.226)
Due to related parties		(57.352)	(72.842)	(504)	4.719
Payment of leased assets	14.2	(3.475)	(3.079)	(21.496)	(16.506)
Capital increase	22 a)	1.778.478	-	1.778.478	-
Capital decrease	22 c)	-	-	(400)	(1.919)
Expenses on public offering of shares	22 a)	(103.999)	-	(103.999)	-
Purchase of treasury shares	22 a)	(28.436)	-	(28.436)	-
Advance for future capital increase	31	-	-	1.590	1.818
Net cash used in financing activities		<u>1.373.463</u>	<u>41.313</u>	<u>1.277.158</u>	<u>331.905</u>
<b>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>		<u><b>1.224.747</b></u>	<u><b>(225.930)</b></u>	<u><b>1.032.591</b></u>	<u><b>222.839</b></u>
Cash and cash equivalents at the beginning of the period / year	5	82.553	315.152	740.829	447.346
Effects of exchange rate changes on cash held in foreign currencies		-	-	(101)	3.402
Cash and cash equivalents at the end of the period	5	<u>1.307.300</u>	<u>89.222</u>	<u>1.773.521</u>	<u>666.783</u>
<b>DECREASE IN CASH AND CASH EQUIVALENTS</b>		<u><b>1.224.747</b></u>	<u><b>(225.930)</b></u>	<u><b>1.032.591</b></u>	<u><b>222.839</b></u>

The accompanying notes are an integral part of this interim financial information.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF VALUE ADDED

FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020

(In thousands of Brazilian reais - R\$)

	Note	Parent		Consolidated	
		09/30/2021	09/30/2020	09/30/2021	09/30/2020
Revenues		147.421	131.677	2.070.245	1.564.937
Provision of services	23	137.162	136.767	2.103.603	1.601.262
Revenue from construction of own assets and leasehold improvements		2.266	487	11.995	8.903
Allowance for expected credit losses and disallowance	23	7.993	(5.577)	(45.353)	(45.228)
Inputs acquired from third parties		(107.647)	(117.758)	(1.424.859)	(1.092.808)
Cost of services		(86.261)	(90.826)	(1.276.795)	(955.660)
Supplies, power, outside services and other inputs		(20.297)	(26.932)	(145.901)	(135.732)
Other		(1.089)	-	(2.163)	(1.416)
Gross value added		39.774	13.919	645.386	472.129
Withholdings		(18.907)	(12.737)	(91.069)	(72.937)
Depreciation and amortization	24	(18.907)	(12.737)	(91.069)	(72.937)
Net wealth		20.867	1.182	554.317	399.192
Wealth received in transfer		40.524	47.616	36.357	15.142
Share of profit (loss) of subsidiaries		16.180	31.802	-	-
Finance income	25	24.344	15.814	36.357	15.142
Total wealth		61.391	48.798	590.674	414.334
Wealth distributed		61.391	48.798	590.674	414.334
Personnel and related taxes		72.671	17.290	276.587	181.406
Salaries and wages		70.446	14.596	222.686	140.905
Benefits		1.744	2.114	41.682	32.414
Severance pay fund (FGTS)		481	580	12.219	8.087
Taxes, fees and contributions		11.040	11.616	214.119	167.993
Federal		6.975	7.514	160.595	124.946
Municipal		4.065	4.102	53.524	43.047
Lenders and lessors		39.872	36.897	145.114	66.624
Finance costs	25	42.802	38.102	128.728	59.714
Occupancy expenses		(2.930)	(1.205)	16.386	6.910
Shareholders		(62.192)	(17.005)	(45.146)	(1.689)
Dividends		-	-	275	2.935
Accumulated losses		(62.192)	(17.005)	(62.192)	(17.005)
Noncontrolling interests in retained earnings		-	-	16.771	12.381

The accompanying notes are an integral part of this interim financial information.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

NOTES TO THE INTERIM FINANCIAL INFORMATION

FOR THE PERIODS ENDED SEPTEMBER 30, 2021 AND 2020

(Amounts in thousands of Brazilian reais - R\$, unless otherwise stated)

---

1. GENERAL INFORMATION

Oncoclínicas do Brasil Serviços Médicos S.A. (“Company”, “Parent” or “Oncoclínicas”), with head office at Avenida Presidente Juscelino Kubitscheck, nº 510, 2º andar, Bairro Vila Nova Conceição, São Paulo – SP, established in 2010, is a publicly-held company since August 2021, listed on the Novo Mercado of B3 S.A. , whose shares are traded under ticker symbol ONCO3. The Company and its subsidiaries (collectively Group” or “Oncoclínicas Group”) provide healthcare services, mainly focused on Oncology.

Since its establishment, the Company, in addition to providing treatment to oncology patients, has been dedicated to analyzing and identifying the most appropriate therapy opportunities for patients and growth trends in the industry.

Oncoclínicas’ mission is to “beat the cancer”.

Since its establishment, the Company has started to pursue an organic and acquisition-based growth strategy. To pursue its growth, Oncoclínicas Group acquired controlling equity interest in clinics, hospitals and precision medicine centers in several Brazilian regions and opened new units in areas with latent demand through partnerships and provision of healthcare and oncology center coordination services in hospitals.

The Company’s controlling shareholders are Josephina Fundo de Investimento em Participações Multiestratégia (“Josephina”) and Josephina II Fundo de Investimento em Participações Multiestratégia (“Josephina II”), in addition to noncontrolling shareholders, including Mr. Bruno Lemos Ferrari. The shareholding structure is shown in note 22.

The Group’s ultimate controlling shareholder is The Goldman Sachs Group, Inc. (“Goldman Sachs”), which is a leading asset investment firm in Brazil, with a diversified portfolio and wide national presence.

Covid 19 pandemic

i. Analysis of the Effects arising from COVID-19 Pandemic on the Company’s Business

The Company's operations have been adversely affected by the effects from COVID-19 pandemic on its operating results, cash flow and drop in care services, due to all the preparations to face the pandemic. The greatest impact of these measures occurred in the second quarter of 2020. In the third quarter of 2021, we saw a resumption of medical care and an 14% reduction in expenses with the purchase of protection materials and tests for employees, compared to the same period of the previous year.

ii. Effects on the Company’s Financial Position and Results of Operations

The Company was financially impacted during the pandemic. The impacts were due to the following factors:

The COVID-19 pandemic reduced the number of patients served throughout the year, especially in the second quarter of 2020. However, in 2021, the Company has already observed a resumption of care services, reaching 96 thousand procedures in the third quarter of 2021, compared to 80 thousand in the same period of the previous year. Extraordinary expenses incurred to face the COVID-19 pandemic in the amount of R\$1,759 in the third quarter of 2021, compared to R\$2,034 in the third quarter of 2020. These expenses involve testing employees for COVID-19 and the purchase of personal protective equipment.

### iii. Measures Adopted as a result of COVID-19

Since the pandemic's onset, the Company has been daily monitoring COVID-19 evolution and impact on its business, and has developed a specific strategic plan comprising:

- (i) the creation of a crisis management committee composed of members from the Board of Directors and executive officers from the Company's main departments.
- (ii) the adoption of all measures deemed necessary to ensure the health and wellness of the Company's employees, including comprehensive and periodic qualification training concerning the safety and treatment of COVID-19-infected patients, especially doctors and non-medical healthcare professionals, as well as the adoption of specific service protocols for patients with symptoms of COVID-19 at the Oncoclínicas Group's hospitals, healthcare centers and laboratories.
- (iii) the acquisition of inventory items comprising materials and medicines for detecting and treating COVID-19-infected patients, as well as personal protective equipment.
- (iv) the adoption of a telemedicine platform to allow continuity of medical services.

### Corporate restructuring

In May 2021, Oncoclínicas Group carried out a corporate restructuring between subsidiaries, without changing equity interests, centralizing the precision medicine and laboratory companies. For this transaction, a Net Assets Valuation Report was prepared, at book values, for each company involved in this corporate restructuring, in order to support the partial spin-off of the net assets of certain indirect subsidiaries with transfer of the book value of these assets for a capital increase in subsidiary Idengene Medicina Diagnóstica S.A. ("Idengene"). The assets involved in the corporate restructuring process are derived from the goodwill arising on the acquisition of interest in the spun-off companies, i.e., Locus, Boston, IRA and Idengene, as well as the investment balances related to the balance of the interest in the spun-off companies, as well as intangible assets comprising acquisition and implementation costs of operating systems. With the new shareholding structure, Idengene became the direct parent of the companies: Instituto Roberto Alvarenga Ltda. ("IRA"), Anatomia Patologia e Citologia Ltda. ("Locus") and Boston Lighthouse ("BLI").

### Acquisitions in progress

- CAM Group/Clion

On April 17, 2021, a Share Purchase and Sale Agreement and Other Covenants, amended on April 23, 2021 ("CCV"), and an Investment Agreement and Other Covenants ("Investment Agreement") were signed under which, and subject to the fulfillment and/or waiver of certain conditions precedent (including

the approval from the Administrative Council for Economic Defense (CADE)), Núcleo de Oncologia da Bahia S.A. (“NOB”), a subsidiary of the Company, undertook to acquire shares representing 100% of the capital of CAM - Clínica de Assistência à Mulher Ltda., Clion - Clínica de Oncologia Ltda., GMN - Grupo de Medicina Nuclear Ltda., Osteo Centro de Diagnostico da Osteoporosis Ltda. and JPC Patologia e Análises Clínicas Ltda. (“CAM Companies” and “CAM Acquisition”, respectively) and certain partners of CAM Companies undertook to reinvest part of the purchase price in NOB (“NOB Investment”, and together with CAM Acquisition, the “Transaction”). The compliance with the conditions precedent has not yet been completed.

The purchase price of all shares issued by the CAM Companies agreed between the parties is R\$324,115, subject to adjustments, and of such amount, the equivalent of R\$65,276 will be reinvested in NOB, pursuant to the Investment Agreement. As a result of this transaction, on the closing date, NOB will hold 100% of the capital of the CAM Companies and certain partners of the CAM Companies will hold common shares representing 12.15% of the capital of NOB.

- Acquisition of Unity

On September 30, 2021, Oncoclínicas do Brasil (“Company”), entered into a binding memorandum of understanding for the acquisition of 100% of the capital of Unity Participações S.A (“Unity”).

The purchase price of Unity, if confirmed, will be R\$558,000 to be paid in cash, in addition to the issuance of 45,765,246 of the Company’s shares, subject to usual confirmation adjustments for transactions of this nature.

The consummation of the transaction is subject to the fulfillment of usual conditions for this type of transaction, including (i) the approval by the Company’s general meeting; (ii) the approval by the Administrative Council for Economic Defense (CADE); and (iii) the execution of final documents.

- Investment agreement - Unimed BH

On September 28, 2021, the Company has signed, through its direct subsidiary Andromeda Participações Ltda., an Investment Agreement with Unimed Belo Horizonte Cooperativa de Trabalho Médico (“Unimed BH”), under which Unimed BH will hold 15% of the capital of Instituto Materno Infantil de Minas Gerais S.A. (“Hospital Vila da Serra”), a hospital fully held by the Company.

The completion of this transaction is subject to conditions precedent usual in this type of transaction, including the approval from CADE.

- Acquisition of UMC – Complexo Hospitalar Uberlândia

On October 1, 2021, the Company completed the acquisition, through its subsidiary Multihemo Serviços Médicos S.A, of 84% of the capital of Complexo Hospitalar Uberlândia S.A. (“UMC”). The purchase price will be R\$242,159, of which R\$40,000 was paid as down payment in September 2021, R\$189,559 will be paid in cash up to the closing date and R\$12,600 will be paid within four years counted from the closing date and adjusted by the CDI.

UMC has acquired together UMC Imagem Ltda and Instituto do Coração do Triângulo Mineiro Ltda:

- 81.4% of the capital of UMC Imagem was acquired for the amount of R\$24,628, of which R\$23,347 to be paid in cash and R\$1,281 will be paid within four years counted from the closing date and adjusted by the CDI.
- 100% of the capital of ICT was acquired for the amount of R\$24,871, of which R\$23,577 to be paid in cash and R\$1,294 will be paid within four years counted from the closing date and adjusted by the CDI.

- Acquisition of Oncobio

On October 1, 2021, the Company has entered into with Bioncologia de Minas S.A. an agreement for the acquisition of the remaining 40% interest in Oncobio Serviços de Saúde S.A. (“Oncobio”), an oncology treatment unit - cancer center – located in Nova Lima, greater Belo Horizonte, Minas Gerais State, for the amount of R\$41,912 (“Transaction”). Upon completion of the transaction, the Company will hold 100% of Oncobio.

The completion of this transaction is subject to conditions precedent usual in this type of transaction, including the approval from CADE.

Partnership

On October 10, 2021, the Company has entered into a Binding Memorandum of Understanding (“MOU”) with Unimed – Rio Cooperativa de Trabalho Médico do Rio de Janeiro Ltda and Unimed Rio Empreendimentos Médicos Hospitalares Ltda, for the establishment of an integrated cancer center at Hospital Unimed (“Cancer Center”).

The Company’s total investment will amount to R\$117,500 over the next two years. The Cancer Center will be managed and controlled by the Company, which will hold 50.01% interest, and Unimed-RJ will hold the remaining 49.99% interest.

## 2. BASIS OF PREPARATION, PRESENTATION OF INTERIM FINANCIAL INFORMATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### 2.1. Statement of compliance

The individual and consolidated interim financial information has been prepared in accordance with technical pronouncement CPC 21 (R1) – “Demonstração Intermediária” and the consolidated interim financial information in accordance with the standards of CPC 21 (R1) and IAS 34 – Interim Financial Reporting issued by the International Accounting Standards Board (IASB) and presented in line with the standards issued by the Brazilian Securities and Exchange Commission (“CVM”), applicable to the preparation of Interim Financial Information (ITR).

All relevant information for the interim financial information, and only this information, is being disclosed and corresponds to the information used in managing the Company.

The accounting practices adopted in Brazil comprise the policies set out in the Brazilian Corporate Law and the pronouncements, guidelines and interpretations issued by the Accounting Pronouncements Committee (CPC) and approved by the CVM and the Federal Accounting Council (CFC).

### 2.2. Basis of presentation

The information related to the bases of preparation and presentation of the interim financial information, the summary of significant accounting policies and the use of estimates and judgments was not subject to changes in relation to that disclosed in the notes to the annual financial statements for the year ended December 31, 2020 (hereinafter referred to as “Financial statements as at December 31, 2020”), therefore, the interim financial information must be read together with the financial statements for the year ended December 31, 2020.

### 2.3. Basis of consolidation

The interim financial information includes the operations of the Company and its subsidiaries, whose direct and indirect percentage equity interests at the balance sheet dates are disclosed as follows:

	Equity interest (%)	
	09/30/2021	12/31/2020
1) Oncobio Serviços de Saúde S.A.	60	60
2) Oncocentro Imagem Serviços Médicos Ltda.	100	100
3) Hematológica - Clínica de Hematologia S.A.	100	58.02
4) Radiogroup Participações S.A.	80	80
5) Radiocare Serviços Médicos Especializadas Ltda.	100	100
6) Centro de Tratamento em Radioterapia Ltda.	100	100
7) Centro de Quimioterapia Antibalística e Imunoterapia S.A.	100	100
8) COT - Centro Oncológico do Triângulo S.A.	65	65
9) COT - Radioterapia Ltda.	100	100
10) Oncocentro Uberlândia S.A.	100	100
11) Oncoclínicas Participações Minas Gerais S.A.	87.75	87.75
12) Núcleo de Hematologia e Transplante Óssea de MG Ltda.	100	100
13) Centro Paulista de Oncologia S.A.	99.5	99.5
14) Radioterapia Oncoclínicas Salvador Ltda.	100	100
15) Oncopar Sul Empreendimentos e Participações Ltda.	100	100
16) Instituto de Hematologia e Oncologia de Curitiba S.A. – Clínica Médica	72	66
17) Centro de Quimioterapia Oncoclínicas S.A.	100	100
18) Oncoclínicas Canoas Clínica de Oncologia Ltda.	90	90
19) Pro Onco Centro de Tratamento Oncológico S.A.	75	75
20) Centro Mineiro de Infusão S.A.	100	100
21) CPO - Centro Paraibano de Oncologia S.A.	99.99	75
22) Núcleo de Oncologia da Bahia S.A.	80.65	79.65
23) Núcleo de Oncologia da Bahia Centro de Prevenção Ltda.	99.95	99.95
24) Núcleo de Oncologia de Sergipe S.A.	100	43.21
25) Multihemo Serviços Médicos S.A.	100	74.37
26) Radioterapia Oncoclínicas Recife S.A.	100	97.6
27) Onco Clínica Recife Ltda.	99.99	99.99
28) Oncoclínica Centro de Tratamento Oncológico S.A.	100	100
29) Radioterapia Botafogo S.A.	100	100
30) Centro de Excelência Oncológica S.A.	50	50
31) Oncologia Participações Ltda.	100	100
32) CECON - Centro Capixaba de Oncologia S.A.	81.5	68
33) Helmond Oncologia S.A.	50	50
34) Oncohematologia Participações Ltda.	100	100
35) Idengene Medicina Diagnóstica S.A.	100	100
36) Instituto de Oncologia de Ribeirão Preto S.A.	86	86
37) Radioterapia Oncoclínicas Ribeirão Preto Ltda.	100	100
38) Radioterapia Oncoclínicas São Paulo Ltda.	100	100
39) Centro de Excelência de RT do Rio de Janeiro S.A.	50	50
40) Central de Gestão e Saúde Ltda.	100	100
41) Oncoclínicas Participações SP Ltda.	100	100
42) Onco Vida Instituto Especializado de Oncologia Clínica S.A.	84.04	60
43) Aliança Instituto de Oncologia S.A.	80	55
44) Oncoclínicas Participações ES RJ Ltda.	100	100
45) Oncoclínicas Rio de Janeiro S.A.	100	100
46) Boston Lighthouse	90.28	90.28
47) Navarra RJ (Leste Fluminense S.A.)	51	51

	Equity interest (%)	
	09/30/2021	12/31/2020
48) Pontus Participações Ltda.	50.01	50.01
49) Yukon Participações S.A.	50.01	50.01
50) Baikal Participações S.A.	50.01	50.01
51) Angara Participações S.A.	50.01	50.01
52) Andrômeda Participações Ltda.	100	100
53) Locus Anat. Patol. e Citologia Ltda.	100	100
54) Hospital de Oncologia do Méier S.A	100	100
55) Ira Instituto Roberto Alvarenga Ltda.	95	95
56) Instituto Materno Infantil de Minas Gerais S.A	100	100
57) Fundo de investimentos em direitos creditórios – FIDC	100	100
58) Oncoclínicas Salvador S.A	100	100
59) Cruz Participações Ltda (Talassa Participações S.A)	50.01	-
60) Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda	100	-
61) CTR Centro de Tratamento Radioterápico Ltda	87.56	-

- 1) Oncobio Serviços de Saúde S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Nova Lima, which is primarily engaged in: the provision of medical services in general, including chemotherapy, radiotherapy, diagnostic and therapeutic activities, outpatient medical activities through resources for surgical procedures and complementary tests, and other human healthcare activities.
- 2) Oncocentro Imagem Serviços Médicos Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other entities that are engaged in the provision of medical services in general.
- 3) Hematológica – Clínica de Hematologia S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of (i) outpatient oncology and oncohematology (chemotherapy) services; (ii) apheresis through automated blood-processing machine; (iii) autologous hematopoietic stem cell transplantation; (iv) blood drawing (phlebotomy); (v) myelogram; (vi) bone marrow biopsy; (vii) outpatient medical appointments; (viii) flow cytometry laboratory - immunophenotyping and cytogenetics; and (ix) cryopreservation of stem cells. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 4) Radiogroup Participações S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other companies and corporations, either as a partner or shareholder.
- 5) Radiocare Serviços Médicos Especializados Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of radiotherapy services and outpatient medical appointments.
- 6) Centro de Tratamento em Radioterapia Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Betim, which is primarily engaged in: the provision of radiotherapy services and diagnostic imaging services (computed tomography, ultrasound, conventional radiology, mammography, magnetic resonance, nuclear medicine, among others), in addition to complementary tests.
- 7) Centro de Quimioterapia Antitumoral e Imunoterapia S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of medical oncology services, especially those involving chemotherapy and related treatments, both at outpatient facilities and hospitals, as well as the management of own assets.
- 8) COT – Centro Oncológico do Triângulo S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Uberlândia, which is primarily engaged in: the provision of medical oncology services such as: clinical care, applications of chemotherapy, radiotherapy, small surgical procedures and oncological emergency care.
- 9) COT Radioterapia Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Uberlândia, which is primarily engaged in: the provision of clinical services in the radiotherapy, imaging and ionizing treatment fields.
- 10) Oncocentro Uberlândia S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Uberlândia, which is primarily engaged in: the provision of medical services in general, specifically including chemotherapy, diagnostic and therapeutic activities, outpatient medical activities through resources for surgical procedures and complementary tests, and other human healthcare activities.
- 11) Oncoclínicas Participações Minas Gerais S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: a) performing medical and hospital assistance, consulting and advisory activities in the hematology, oncology, chemotherapy and bone marrow transplantation fields; and (b) holding equity interests in other entities of any nature, either as a partner or shareholder, in Brazil or abroad.
- 12) Núcleo de Hematologia e Transplante de Medula Óssea de Minas Gerais Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of medical and hospital assistance, consulting and advisory services in the hematology, oncology, chemotherapy, clinical analysis laboratory and bone marrow transplantation fields.
- 13) Centro Paulista de Oncologia S.A. is a privately-held corporation located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: (i) the provision of medical services, specifically those involving the oncology, hematology and chemotherapy fields, as well as oncology and hematology diagnostics and therapies; (ii) advisory and consulting services in the oncology and hematology fields; (iii) infusion of non-oncological medicines; (iv) non-oncological medical appointments; (v) collection, storage and processing of biological samples; and (vi) holding equity interests in other entities and joint ventures, either as a partner or shareholder, provided that they are engaged in activities related to its corporate purposes.
- 14) Radioterapia Oncoclínicas Salvador Ltda. is a limited liability company located in Brazil, in the State of Bahia, city of Salvador, which is primarily engaged in: the provision of radiotherapy services, including hospital care activities, except for emergency room and emergency care units, and outpatient medical activities through resources for the performance of complementary tests.

## Oncoclínicas do Brasil Serviços Médicos S.A.

- 15) Oncopar Sul Empreendimentos e Participações Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other entities, either as a partner or shareholder, besides operating as a holding company of non-financial institutions.
- 16) Instituto de Hematologia e Oncologia Curitiba – Clínica Médica S.A. is a privately-held corporation located in Brazil, in the State of Paraná, city of Curitiba, which is primarily engaged in: the provision of chemotherapy services, including outpatient medical activities through resources for surgical procedures. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 17) Centro de Quimioterapia Oncoclínicas S.A. is a privately-held corporation located in Brazil, in the State of Rio Grande do Sul, city of Porto Alegre, which is primarily engaged in: the provision of medical services, including, but not limited to, oncology, chemotherapy, hemotherapy and medical diagnosis and therapy services in general.
- 18) Oncoclínicas Canoas Clínica de Oncologia Ltda. is a limited liability company located in Brazil, in the State of Rio Grande do Sul, city of Canoas, which is primarily engaged in: the provision of medical care services in the clinical oncology and outpatient chemotherapy fields, including all related treatments.
- 19) Pro-Onco Centro de Tratamento Oncológico S.A. is a privately-held corporation located in Brazil, in the State of Paraná, city of Londrina, which is primarily engaged in: the provision of chemotherapy services and medical, hospital services intended for the oncological treatment of patients.
- 20) Centro Mineiro de Infusões S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of medical services in general, specifically including hemotherapy, diagnostic and therapeutic activities, outpatient medical activities through resources for surgical procedures and complementary tests, and other human healthcare activities.
- 21) CPO – Centro Paraibano de Oncologia S.A. is a privately-held corporation located in Brazil, in the State of Paraíba, city of João Pessoa, which is primarily engaged in: the provision of medical oncology services, besides operating as a day hospital that offers hospitalization services for the chemotherapy treatment of patients. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 22) Núcleo de Oncologia da Bahia S.A. is a privately-held corporation located in Brazil, in the State of Bahia, city of Salvador, which is primarily engaged in: the provision of medical and hospital services in general, specifically including hematology and oncology-related activities and comprising patient care, diagnosis, therapy, emergency, life support, surgical, hospitalization procedures, among others. There was a change made through a purchase and sale agreement among Centro Mineiro de Infusões and noncontrolling shareholder, whereby 1% of the capital and 60,453 common shares were acquired. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 23) Núcleo de Oncologia da Bahia Centro de Prevenção Ltda. is a limited liability company located in Brazil, in the State of Bahia, city of Salvador, which is primarily engaged in: holding equity interests in other entities, either as a partner or shareholder, besides operating as a holding company of non-financial institutions.
- 24) NOS – Núcleo de Oncologia de Sergipe S.A. is a privately-held corporation located in Brazil, in the State of Sergipe, city of Aracaju, which is primarily engaged in: outpatient medical activities through resources for complementary tests, outpatient medical activities restricted to appointments, provision of chemotherapy services, provision of hematology services, bone marrow biopsies and myelogram, nursing activities, nutrition professional activities, psychology and psychoanalysis activities, experimental research and development in physical and natural sciences, of a non-commercial medical nature, physiotherapy activities, algology activities, provision of palliative care; and biological therapies. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 25) Multihemo Serviços Médicos S.A. is a privately-held corporation located in Brazil, in the State of Pernambuco, city of Recife, which is primarily engaged in: the provision of medical services in hematology, hemotherapy, cancerology, medical clinic and chemotherapy, besides promoting teaching and research in the hematology, hemotherapy and cancerology-related fields. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 26) Radioterapia Oncoclínicas Recife S.A. is a privately-held corporation located in Brazil, in the State of Pernambuco, city of Recife, which is primarily engaged in: (i) the provision of radiotherapy services; (ii) hospital care activities, except for emergency room and emergency care units; and (iii) outpatient medical activities through resources for the performance of complementary tests. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 27) Onco Clínica Recife Ltda. is a limited liability company located in Brazil, in the State of Pernambuco, city of Recife, which is primarily engaged in: the provision of medical services in the Clinical Oncology, Surgical Oncology, Hematology and Internal Medicine fields.
- 28) Oncoclínica – Centro de Tratamento Oncológico S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: the provision of medical services in general, including chemotherapy, radiotherapy and radiosurgery services, as well as inpatient healthcare and care for patients in need of scheduled direct assistance.
- 29) Radioterapia Botafogo S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: the provision of medical treatment services through ionizing radiation, as well as in the import of medical materials, related materials and accessories for own use, besides rendering hospital services, including the monitoring of hospitalizations at its facilities or at third-party hospitals.
- 30) Centro de Excelência Oncológica S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: (i) the provision of medical and hospital services relating to the oncohematology, oncology and clinical fields, which includes the dispensing of infusion or oral antineoplastic drugs, antineoplastic procedures and radiotherapy, covering care, diagnosis, therapy, emergency and life support procedures; and (ii) holding equity interests in other entities and consortia engaged in the provision of medical services in general.
- 31) Oncologia Participações Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other entities, either as a partner or shareholder, besides operating as a holding company of non-financial institutions.
- 32) CECOM – Centro Capixaba de Oncologia S.A. is a privately-held corporation located in Brazil, in the State of Espírito Santo, city of Vitória, which is primarily engaged in: the provision of medical and hospital services, mainly related to the clinical and surgical oncology and chemotherapy specialties to support the diagnosis and therapy procedures for its patients. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 33) Helmond Oncologia S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: (i) the provision of medical and hospital services relating to the oncohematology, oncology and clinical fields, which includes the dispensing of infusion or oral antineoplastic drugs, antineoplastic procedures and radiotherapy, covering care, diagnosis, therapy, emergency and life support procedures; and (ii) holding equity interests in other entities and consortia engaged in the provision of medical services in general.
- 34) Oncohematologia Participações Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other entities, either as a partner or shareholder.
- 35) Idogene Medicina Diagnóstica S.A. is a privately-held corporation located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: (i) the provision of oncogenetics services, including, but not limited to, DNA sequencing and molecular testing for diagnostic and research purposes, as well as the development and sale of molecular tests based on the analysis of DNA, RNA and/or proteins, carried out on own account or through third parties; (ii) holding courses and seminars in the medical and biological fields, focused on oncogenetics; (iii) medical and biological research development, focused on oncogenetics; (iv) the

- provision of advisory services in the oncogenetics area, including molecular, genomic and medical biology; and (v) holding equity interests in other entities, either as a partner or shareholder.
- 36) Instituto Oncológico de Ribeirão Preto S.A. is a privately-held corporation located in Brazil, in the State of São Paulo, city of Ribeirão Preto, which is primarily engaged in: the provision of chemotherapy and radiotherapy services and medical and hospital activities, such as clinical procedures, including multidisciplinary medical activities, diagnostic imaging services with and without the use of ionizing radiation, computed tomography and holding equity interests in other entities, either as a partner or shareholder.
- 37) Radioterapia Oncoclínicas Ribeirão Preto Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of Ribeirão Preto, which is primarily engaged in: (i) the provision of radiotherapy services; (ii) hospital care activities, except for emergency room and emergency care units; and (iii) outpatient medical activities through resources for the performance of complementary tests.
- 38) Radioterapia Oncoclínicas São Paulo Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: the provision of radiotherapy services, including hospital care activities, except for emergency room and emergency care units, and outpatient medical activities through resources for the performance of complementary tests.
- 39) Centro de Excelência de RT do Rio de Janeiro S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: the provision of medical treatment services through ionizing radiation, as well as in the import of medical materials, related materials and accessories for own use, besides rendering hospital services, including the monitoring of hospitalizations at its facilities or at third-party hospitals.
- 40) Central de Gestão e Saúde Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: (i) health management supporting activities; (ii) auxiliary activities involving insurance, private pension and healthcare plans in general; and (iii) human care activities in general.
- 41) Oncoclínicas Participações São Paulo Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: holding equity interests in other entities, either as a partner or shareholder, besides operating as a holding company of non-financial institutions.
- 42) Onco Vida Instituto Especializado de Oncologia S.A. is a privately-held corporation located in Brazil, in the Federal District, city of Brasília, which is primarily engaged in: the provision of services in the several medical, clinical and surgical fields, conducting outpatient and hospital activities, which include medical appointments and outpatient clinical and surgical procedures. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 43) Aliança Instituto de Oncologia S.A. is a privately-held corporation located in Brazil, in the Federal District, city of Brasília, which is primarily engaged in: the provision of medical services, either at own or third-party facilities, involving the following specialties: a) Oncology, both clinical (including chemotherapy) and hospital (including surgeries); b) Rheumatology; c) Hematology; d) Immunotherapy; e) Administration of supportive medications such as antibiotics, antifungal, antiviral drugs; f) Outpatient Surgeries; g) Diagnosis of hematological diseases; h) Gynecology; i) Cardiology; j) Head and neck surgery; k) General surgery; l) Infectious diseases; m) Genetics; n) Mastology; o) Vaccine application; p) Psychiatry; q) Orthopedics; r) Endocrinology; s) Gastroendocrinology; t) performance of invasive medical examinations; and u) healthcare center services in general and other specialties and services in the medical and non-medical professional segment. During the six-month period ended June 30, 2021, the Group acquired an additional interest in this subsidiary as disclosed in note 11.
- 44) Oncoclínicas Participações RJ ES Ltda. is a limited liability company located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: holding equity interests in other entities of any nature, either as a partner or shareholder, in Brazil or abroad; and management and sale of own assets.
- 45) Oncoclínicas Rio de Janeiro S.A. is a limited liability company located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: the provision of outpatient medical services in the clinical oncology field, including chemotherapy services and specialized examinations for prevention, research and diagnosis, therapy and treatment of oncological diseases.
- 46) Boston Lighthouse Innovations, Inc. is a Corporation located in the United States, County of Sussex, Delaware, which is primarily engaged in: the development and sale of genomic bioinformatics methods.
- 47) Navarra RJ Serviços Oncológicos S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Niterói, which is primarily engaged in: (a) the provision of chemotherapy services; (b) the provision of outpatient medical services; (c) the development and direct performance of activities relating to medical, hospital and healthcare services; (d) the provision of all and any services involving the acquisition or import of all and any pieces of equipment, machinery, materials and inputs required for the performance of said activities; and (e) the performance of any related or accessory activities or activities deemed necessary to achieve the company's corporate purpose.
- 48) Pontus Participações S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: holding equity interests in other companies and corporations, either as a partner or shareholder.
- 49) Yukon Oncologia e Participações S.A. is a privately-held corporation located in Brazil, in the State of Bahia, city of Salvador, which is primarily engaged in: (i) the provision of medical and hospital services in general, specifically including hematology and oncology-related activities and comprising patient care, diagnosis, therapy, emergency, life support, surgical, hospitalization procedures, among others; and (ii) holding equity interests in other companies and corporations, either as a partner or shareholder.
- 50) Baikol Oncologia e Participações S.A. is a privately-held corporation located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: (i) the provision of medical and hospital services in general, specifically including hematology and oncology-related activities and comprising patient care, diagnosis, therapy, emergency, life support, surgical, hospitalization procedures, among others; and (ii) holding equity interests in other companies and corporations, either as a partner or shareholder.
- 51) Angará Oncologia e Participações S.A. is a privately-held corporation located in Brazil, in the Federal District, city of Brasília, which is primarily engaged in: (i) the provision of medical and hospital services in general, specifically including hematology and oncology-related activities and comprising patient care, diagnosis, therapy, emergency, life support, surgical, hospitalization procedures, among others; and (ii) holding equity interests in other companies and corporations, either as a partner or shareholder.
- 52) Andrômeda Participações Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: holding equity interests in other entities of any nature, either as a partner or shareholder, in Brazil or abroad; and management and sale of own assets.
- 53) Locus – Anatomia Patológica e Citologia Ltda. is a limited liability company located in Brazil, in the State of São Paulo, city of São Paulo, which is primarily engaged in: The provision of pathological and cytological anatomy services intended to support treatment and diagnosis processes, including related and supplementary services.
- 54) Hospital de Oncologia do Méier S.A. is a privately-held corporation located in Brazil, in the State of Rio de Janeiro, city of Rio de Janeiro, which is primarily engaged in: (i) medical and hospital services in several specialties, including oncology, radiotherapy, surgical procedures, healthcare center and medical assistance, appointments and hospitalizations; (ii) emergency room care, operation of hospital units for emergencies and mobile ICU; (iii) laboratory and imaging diagnostics, x-ray, endoscopy, ultrasound, tomography and similar services; and (iv) the provision of supplementary services for supporting the aforesaid activities, including the direct and indirect operation of parking lots.
- 55) IRA Instituto Roberto Alvarenga Ltda. is a limited liability company located in Brazil, in the State of Minas Gerais, city of Belo Horizonte, which is primarily engaged in: the provision of services involving activities of the pathological-cytological anatomy laboratories.

- 56) Instituto Materno Infantil de Minas Gerais S.A. is a privately-held corporation located in Brazil, in the State of Minas Gerais, city of Nova Lima, which is primarily engaged in: hospital care activities, including emergency room and hospital units for emergency care; hospital management advisory services; development of scientific activities and medical training; lease or sublease of its physical-structural area necessary to provide supplementary services in connection with medical and hospital services and human health assistance. Finally, the Company may acquire equity interest in other entities, provided that these entities are engaged in activities similar to its corporate purpose.
- 57) The FIDC establishment is exclusively intended for the Group's companies to conduct investments and assignments of receivables. As at December 31, 2020, the Group holds 100% of the Fund's units. Oncoclínicas and its subsidiaries will be in charge of acquiring the FIDC's units. The Fund's asset portfolio comprises Oncoclínicas Group's loan agreements and fixed-income investments. The Fund is effective for an indefinite term and may be settled as approved at the General Meeting, pursuant to the Fund's Regulation. The Fund's net assets will be comprised of a single class of units. The FIDC's acquired units are initially measured at fair value and subsequently measured at amortized cost, in accordance with CPC 48 – Financial Instruments, since: (i) according to the proposed business model, the FIDC's unitholders should hold their units to maturity so as to collect contractual cash flows; and (ii) on the redemption date, the amount of FIDC's units should be measured at the acquisition cost, plus income earned, using the rate applicable to the acquisition of receivables and investments in other financial instruments. FIDC is a special-purpose entity whose operations will be substantially conducted as per the operating requirements of Oncoclínicas Group, which will be exposed to most related risks and rewards. In accordance with CVM Instruction 408/04, the Company consolidates the financial statements of FIDC Oncoclínicas, a special-purpose entity whose operations are substantially conducted as per the operating requirements of the Company, which, given the ownership of all subordinated units, was exposed to most risks and rewards underlying the fund.
- 58) Oncoclínicas Salvador S.A is a privately-held corporation located in Brazil, in the State of Salvador, which is primarily engaged in: the provision of radiotherapy services, including hospital care activities, except for emergency room and emergency care units, and outpatient medical activities through resources for the performance of complementary tests.
- 59) Talassa Participações S.A is a privately-held corporation located in Brazil, in the State of Santa Catarina, Florianópolis, which is primarily engaged in: the provision of chemotherapy and radiotherapy services; the provision of outpatient medical services, the development and direct and indirect performance of activities relating to medical, hospital and healthcare services; the provision of all and any services involving the acquisition or import of all and any pieces of equipment, machinery, materials and/inputs required for the performance of said activities; and the performance of any related or accessory activities or activities deemed necessary to achieve the company's corporate purpose. This subsidiary was established as a vehicle to regulate the joint investment of the Company and UGF through UGF Par, in Talassa (see note 13).
- 60) Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda is a limited liability company, with head office in the city of Goiânia, State of Goiás, which is engaged in the provision of radiotherapy, oncology, mastology and related treatment and diagnosis services. This company was acquired in September 2021 (see note 4)
- 61) CTR Centro de Tratamento Radioterápico Ltda is a limited liability company, with head office in the city of Goiânia, State of Goiás, which is engaged in the provision of radiotherapy healthcare services. This company was acquired in September 2021 (see note 4)

The Company consolidates all entities over which it holds control , that is, when the Company has:

- (a) power over an investee;
- (b) exposure, or rights, to variable returns from its interest in the investee, and
- (c) the ability to use its power over the investee to affect the amount of the investor's returns.

The Company reassesses whether or not it retains control of an investee if facts and circumstances indicate the occurrence of changes in one or more of the three elements of control listed above.

The consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ends when the Company loses control over the subsidiary. Specifically, the income and expenses of a subsidiary acquired or sold during the year are included in profit or loss from the date on which the Company obtains control until the date on which the Company no longer controls the subsidiary.

When necessary, adjustments are made to the subsidiaries' financial statements to bring their accounting policies into line with the Group's accounting policies.

In the consolidation, the parent company's interest in the subsidiaries' equity, as well as the balances of assets and liabilities, income and expenses arising from intragroup transactions, were eliminated.

### 3. NEW AND REVISED STANDARDS AND INTERPRETATIONS

There are no CPC/IFRS standards or ICPC interpretations/ International Financial Reporting Interpretations Committee ("IFRIC") recently issued, applicable to the Company, which have been adopted in the current period by the Company and its subsidiaries.

Standards issued but not yet effective

There were no new standards issued but not yet effective other than those already disclosed in the annual financial statements.

## 4. BUSINESS COMBINATIONS

The fair value of assets acquired and liabilities assumed in business combinations during 2021, as well as the fair value of identifiable assets and goodwill recognized were accounted for on provisional basis, and the goodwill will be finally determined within a period of twelve months. These amounts are as follows:

Location	Goiás	Goiás
Company	Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda.	CTR Centro de Tratamento Radioterápico Ltda.
Acquisition date	09/01/2021	09/09/2021
Equity interest acquired (voting %)	100%	87.56%
Noncontrolling interests	-	12.44%
Payment on acquisition date	94,000	28,386
Payables for acquisitions	91,678	27,537
Total consideration	185,678	55,923
Assets acquired	41,955	6,952
Cash and cash equivalents	1,080	674
Trade receivables	5,023	524
Inventories	578	-
Recoverable taxes	2,125	49
Property and equipment	17,282	2,195
Intangible assets	1,048	72
Leases	1,644	-
Indemnities – Contingencies	12,800	-
Other assets	335	3,438
Liabilities assumed	36,151	3,034
Trade and other payables	11,649	44
Payroll and related taxes	1,736	312
Taxes payable	363	108
Borrowings	8,350	2,564
Leases	1,644	-
Contingencies	12,800	-
Other	1,609	6
Total net assets acquired	3,764	3,918
Noncontrolling shareholders		487
Excess price paid on the acquisition	181,915	52,492
Contribution to line item “Revenue” since the acquisition date	10,958	1,085

Contribution to line item profit (loss) before taxes since the acquisition date	1,002	489
Acquiree's revenue since the beginning of the current year	81,240	9,310
Acquiree's profit (loss) before taxes since the beginning of the year	7,860	5,345

#### Acquisitions in 2021

##### (a) Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda

Refers to the purchase and sale agreement providing for the control and effective acquisition of Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda by Oncoclínica – Centro de Tratamento Oncológico S.A (CTO), on September 1, 2021. It is located in Goiás and engaged in the provision of radiotherapy, oncology, mastology and related treatment and diagnosis services.

#### Negotiated price

Pursuant to the purchase and sale agreement, 100% of the shares comprising the capital of Cebrom was acquired by CTO for R\$185,678.

#### Goodwill on business combination

For the purposes of this business combination, the amount of R\$181,915 was recognized as goodwill based on expected future earnings by buyer Oncoclínica – Centro de Tratamento Oncológico S.A.

##### (b) CTR Centro de Tratamento Radioterápico Ltda

Refers to the purchase and sale agreement providing for the control and effective acquisition of CTR Centro de Tratamento Radioterápico Ltda by Oncoclínica – Centro de Tratamento Oncológico S.A (CTO), on September 9, 2021. It is located in Goiás and engaged in the provision of radiotherapy healthcare services.

#### Negotiated price

Pursuant to the purchase and sale agreement, 87.56% of the shares comprising the capital of Cebrom was acquired by CTO for R\$55,923.

#### Goodwill on business combination

For the purposes of this business combination, the amount of R\$52,492 was recognized as goodwill based on expected future earnings by buyer Oncoclínica – Centro de Tratamento Oncológico S.A.

The initial recognition of goodwill arising on the acquisitions above was made on provisional basis, based on the information available up to the end of the reporting period and the Company is gathering the information necessary for the determination of the final amount within the period prescribed in IFRS 3. Trade receivables may significantly impact such determination due to the alignment of the acquirees' accounting practices with those of the Company, which is still in progress.

#### Changes in acquisitions made in 2020

##### (a) Hospital Vila da Serra

During the nine-month period ended September 30, 2021, the Group carried out an assessment of the acquiree's litigation, determining a fair value of R\$14,661 referring to "possible" causes, and according

to the purchase documents, any materialized contingencies are indemnifiable by the former selling controlling shareholders of Hospital Vila da Serra. In compliance with IFRS 3/CPC 15, which establishes that contingent liabilities identified in a business combination must be recognized in the acquirer's financial statements at their respective fair values, the Company recognized said amount.

Also, according to the Purchase Price Allocation (PPA), the method for calculation of the revenue from services of Hospital Vila da Serra in 2020 was reviewed to adjust the accounting practices adopted by the Company. The impacts arising from the review on the acquiree's financial statements as at November 30, 2020 resulted in a decrease in goodwill of R\$9,694, increase in trade receivables in the amount of R\$15,426 and taxes payable in the amount of R\$5,732.

The purchase price allocation and goodwill measurement based on expected future earnings on the acquisition of interest in Hospital Vila da Serra were as follows:

December 31, 2020	Previously stated	Current
Consideration offered	165,319	165,319
Amount of net assets acquired	1,255	10,949
Goodwill	164,064	154,370

(b) Hospital Marcos Moraes

During 2021, the fair value of assets acquired and liabilities assumed, as well as the fair value of identifiable assets of the acquisition of Hospital de Oncologia do Méier – Marcos Moraes, were finally determined and calculated based on the financial position on the acquisition date on July 31, 2020 through the Purchase Price Allocation (PPA). An increase in goodwill in the amount of R\$9,084 was recognized, broken down as a decrease in financial position of R\$5,221 and increase in consideration of R\$3,863.

The purchase price allocation and goodwill measurement based on expected future earnings on the acquisition of interest in Hospital Marcos Moraes were as follows:

December 31, 2020	Previously stated	Current
Consideration offered	64,000	67,863
Amount of net assets acquired	53,663	48,442
Goodwill	10,337	19,421

The Company restated the balances for the comparative period of December 31, 2020, according to the requirement of technical pronouncement CPC 15 (IFRS 3), as follows:

December 31, 2020				Parent
Assets	Previously stated	Adjustment	Restated	Liabilities and equity
Current	190,795	-	190,795	Current
Investments in subsidiaries	763,834	1,932	765,766	Noncurrent
	338,058	-	338,058	585,611
				585,611

<b>Noncurrent</b>	<b>1,132,713</b>	<b>1,932</b>	<b>1,134,645</b>				
				Accumulated losses	(289,784)	1,932	(287,852)
				Equity attributable to owners of the Company	<b>399,839</b>	<b>1,932</b>	<b>401,771</b>
<b>Total assets</b>	<b>1,323,508</b>	<b>1,932</b>	<b>1,325,400</b>	<b>Total liabilities and equity</b>	<b>1,323,508</b>	<b>1,932</b>	<b>1,325,400</b>

December 31, 2020

Consolidated

Assets	Previously stated	Adjustment	Restated	Liabilities and equity	Previously stated	Adjustment	Restated
<b>Current</b>				<b>Current</b>			
Cash and cash equivalents	740,788	41	740,829	Trade payables	345,686	115	345,801
Trade receivables	481,264	15,426	496,690	Payroll and related taxes	63,746	1,540	65,286
Inventories	37,461	(394)	37,067	Taxes payable	84,571	871	85,442
	<b>1,412,255</b>	<b>15,073</b>	<b>1,427,328</b>	Income tax and social contribution payable	22,732	4,861	27,593
					<b>1,013,906</b>	<b>7,387</b>	<b>1,021,293</b>
<b>Noncurrent</b>				<b>Noncurrent</b>			
Deferred income tax and social contribution	31,415	1,367	32,782	Provisions for tax, labor and civil risks	5,405	14,661	20,066
Other assets	33,515	14,661	48,176	<b>Total liabilities</b>	<b>2,685,352</b>	<b>22,048</b>	<b>2,707,401</b>
Property and equipment	393,795	(4,580)	389,215	<b>Equity</b>			
Intangible assets	1,208,647	(610)	1,208,037	Accumulated losses	(289,784)	1,932	(287,852)
Rights of use of leased assets	220,620	-	220,620	Equity attributable to noncontrolling interests	<b>399,839</b>	<b>1,932</b>	<b>401,771</b>
	<b>1,950,403</b>	<b>10,838</b>	<b>1,961,241</b>		<b>277,467</b>	<b>1,931</b>	<b>279,399</b>
				<b>Total equity</b>	<b>677,306</b>	<b>3,863</b>	<b>681,169</b>
<b>Total assets</b>	<b>3,362,658</b>	<b>25,911</b>	<b>3,388,569</b>	<b>Total liabilities and equity</b>	<b>3,362,658</b>	<b>25,911</b>	<b>3,388,569</b>

## 5. CASH AND CASH EQUIVALENTS

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Cash and banks	250	1,176	18,736	16,692
Short-term investments (i)	<u>1,307,050</u>	<u>81,377</u>	<u>1,754,785</u>	<u>724,137</u>
Total cash and cash equivalents	<u>1,307,300</u>	<u>82,553</u>	<u>1,773,521</u>	<u>740,829</u>

- (i) Short-term investments are mainly represented by Bank Deposit Certificates (CDBs) yielding interest corresponding to rates of up to 102.62% in 2021 (99.65% as at December 31, 2020) of the Interbank Deposit Certificate (CDI) rate, highly liquid.

## 6. SECURITIES AND OTHER FINANCIAL ASSETS

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Short-term investments pledged as collaterals for loans (i)	-	46,206	-	46,206
Short-term investments (ii)	489	350	33,659	32,795
<b>Total</b>	<b>489</b>	<b>46,556</b>	<b>33,659</b>	<b>79,001</b>
Current	-	46,206	-	46,206
Noncurrent	489	350	33,659	32,795

- (i) The short-term investments have been pledged as collaterals for the loan obtained from Citibank, yielding interest equivalent to 100% of the CDI rate, which was settled in advance in March 2021.
- (ii) Short-term investments are represented by R\$12,577 as at September 30, 2021 (R\$11,672 as at December 31, 2020) relating to funds held in long-term investments held by Aliança Instituto de Oncologia S.A. at Old Mutual International, R\$1,530 and R\$217 at September 30, 2021 (R\$1,505 and R\$213 as at December 31, 2020) refer to capital accounts in Radioterapia Recife Ltda. e Núcleo de Oncologia de Sergipe S.A. (NOS) with BNB, R\$843 as at September 30, 2021 (R\$842 as at December 31, 2020) refer to the Group's funds invested in financial institutions Unicred and Sicoob and R\$18,492 (R\$18,563 as at December 31, 2020) represents the investment in fixed-income investment fund. This investment, made in September 2020, comprises the investment portfolio of FIDC Oncoclínicas, which is managed by BRL Trust Distribuidora de Títulos e Valores Mobiliários S.A. Investments yield interest of up to 99% of the CDI rate and FIDC up to 2.64% p.a. for the nine-month period of 2021 and up to 107% of the CDI rate and 0.62% p.a. as at December 31, 2020.

## 6.1 Financial instrument

<u>Assets</u>	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Derivatives instruments - swap	-	2,549	-	2,549
<u>Liabilities</u>				
Derivatives instruments - swap	-	-	6,129	-
Current	-	-	3,158	-
Noncurrent	-	-	2,971	-

The Company carried out a swap transaction to hedge the borrowing obtained from Banco Citibank in U.S. dollar against currency fluctuations (see note 16). Such financial instrument was measured at fair value through profit or loss, and the balance as at September 30, 2021 is a liability of R\$6,129.

Details on the derivative financial instruments contracted by the Group are as follows:

2021

The swap transaction was carried out in March 2021, maturing within a 18-month period. Such financial instrument is measured at fair value through profit or loss. As at September 30, 2021, the curve value is a liability of R\$5,736. The average finance charges are equivalent to approximately

100% of the CDI rate + 2.67% p.a. The long and short positions are disclosed in note 28.

## 2020

The swap transaction was carried out in April 2020, maturing within a 12-month period. Such financial instrument is measured at fair value through profit or loss. The swap was settled in March 2021. As at December 31, 2020, the curve value is R\$3,717. The average finance charges are equivalent to approximately 100% of the CDI rate + 3.20% p.a. The long and short positions are disclosed in note 28.

## 7. TRADE RECEIVABLES

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Trade receivables	16,648	18,898	278,333	172,352
Unbilled revenues	22,634	19,083	427,563	393,458
Total trade receivables and unbilled revenues	39,282	37,981	705,896	565,810
Allowance for expected credit losses (ECL)	(3,763)	(11,234)	(27,213)	(34,580)
Provision for disallowance	(1,608)	(1,743)	(33,399)	(34,540)
	33,911	25,004	645,284	496,690

Trade receivables are denominated in Brazilian reais and refer mainly to healthcare services provided to health insurance plans, which average days sales outstanding is 87 days as at September 30, 2021 (85 days as at December 31, 2020).

The aging list of trade receivables is as follows:

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Current	31,849	20,523	465,386	361,714
Up to 30 days past-due	993	2,077	93,759	80,480
Up to 60 days past-due	492	443	45,795	31,249
Up to 90 days past-due	1,535	443	38,661	28,056
91 to 180 days past-due	417	2,351	40,130	18,117
Over 180 days past-due	3,996	12,144	22,165	46,194
	39,282	37,981	705,896	565,810

The Company usually recognizes an allowance for expected credit losses based on the expected collection of trade receivables and the history of losses and disallowed amounts (average of 3% in the allowance calculation) identified by some health insurance plans.

The disallowance occurs upon authorization of the health insurance plan for issuance of the invoice. Once the disallowance is recognized, it is analyzed, and if undue, an appeal is filed with the healthcare operator for the receivable collection. The period for filing of appeals varies according to the healthcare operator, but starts to be counted when the appeal is filed.

Variations in the allowance for expected credit loss and provision for disallowances are as follows:

	Parent	Consolidated
Balance as at December 31, 2019	(6,277)	(54,213)
Reversal	114	44,132
Recognition	(4,407)	(58,168)

	<u>Parent</u>	<u>Consolidated</u>
Balance as at September 30, 2020	<u>(10,570)</u>	<u>(68,249)</u>
Balance as at December 31, 2020	(12,977)	(69,120)
Reversal	11,642	69,685
Recognition	(4,036)	(61,177)
Balance as at September 30, 2021	<u><u>(5,371)</u></u>	<u><u>(60,612)</u></u>

The maximum exposure to credit risk at the reporting date is the carrying amount of each class of receivables mentioned above. Oncoclínicas Group does not have any security pledged as collateral for trade receivables.

#### 8. INVENTORIES

	<u>Parent</u>		<u>Consolidated</u>	
	<u>09/30/2021</u>	<u>12/31/2020</u>	<u>09/30/2021</u>	<u>12/31/2020</u>
Medicines	2,467	834	36,706	18,699
Material and Personal Protective Equipment (PPE)	9,418	6,986	18,669	18,368
Advance	-	-	79	-
Total	<u><u>11,885</u></u>	<u><u>7,820</u></u>	<u><u>55,454</u></u>	<u><u>37,067</u></u>

Inventories refer mainly to medicines used in chemiotherapeutic procedures. There is no allowance for inventory losses and guarantees, considering an average turnover period of approximately 38 days as at September 30, 2021 (36 days as at December 31, 2020) and guarantees provided and/or restrictions on the full use of inventories.

#### 9. RECOVERABLE TAXES

Recoverable taxes are broken down as follows:

	<u>Parent</u>		<u>Consolidated</u>	
	<u>09/30/2021</u>	<u>12/31/2020</u>	<u>09/30/2021</u>	<u>12/31/2020</u>
Income tax (IRPJ) and Social contribution (CSLL)	6,958	5,770	27,021	21,883
Withholding income tax (IRRF)	11,425	5,559	34,504	19,691
Taxes on revenue (PIS and COFINS)	1,614	1,799	37,191	35,136
Service tax (ISS)	-	-	1,880	2,450
Other taxes	32	-	382	358
	<u><u>20,029</u></u>	<u><u>13,128</u></u>	<u><u>100,978</u></u>	<u><u>79,518</u></u>

#### 10. OTHER ASSETS

	<u>Parent</u>		<u>Consolidated</u>	
	<u>09/30/2021</u>	<u>12/31/2020</u>	<u>09/30/2021</u>	<u>12/31/2020</u>
Advances to suppliers	2,843	4,163	2,203	8,768
PERT under consolidation (a)	1,633	1,633	20,234	20,234

Disposal of equity interests (c)	18,643	13,405	20,377	15,216
Advance – acquisitions (e)	-	-	40,000	-
Machinery lease	2,825	2,660	599	720
Sundry advances (b)	893	317	18,294	2,409
Prepaid expenses	7,982	1,909	9,369	3,130
Other (d)	229	950	38,168	22,168
	<u>35,048</u>	<u>25,037</u>	<u>149,244</u>	<u>72,645</u>
Current	15,233	11,188	64,041	24,469
Noncurrent	19,815	13,849	85,203	48,176

(a) Pursuant to §2, Art.2 of Law 13,496/17, which introduced the Special Tax Regularization Program (PERT), the possibility of using tax loss carryforwards CSLL (BCN), calculated up to December 31, 2015, own or of subsidiaries, either directly or indirectly, was disclosed in note 18 (i).

(b) In May 2021, a Private Agreement of Atypical Lease of non-residential property was signed, under the Built To Suit modality between Hymalaia Empreendimentos Imobiliários S.A. (Lessor) and Oncoclínicas – Centro Tratamento Oncológico S.A. (Lessee). As provided for in the contract, the Group paid R\$13,500 as advance lease, corresponding to the first six months of the initial contractual term. The purpose of this agreement is the development, in the Properties, of a mixed-use real estate project planned with the integration of spaces for health, shopping mall, residential and commercial buildings, convention center, leisure, gastronomy and culture, as well as parking lot for approximately 1,800 vehicles ("Mixed Use Enterprise"), which will be economically explored by the Company or by whom it appoints/contracts, ensuring vacancies exclusively for the hospital unit that will be built and leased for use and operation by the Company. The Lease term will start on the date of delivery of the property in conditions of use with a term of 30 (thirty) years.

The project is still in progress, and the recognition criteria prescribed by IFRS 16 (CPC 06) were not yet met.

(c) The equity interest purchase and sale transactions between the Company, its subsidiaries and third parties are shown below. Balances are adjusted based on the CDI + IPCA and mature up to 2030.

<u>Lender</u>	<u>Disposal of equity interest</u>	<u>09/30/2021</u>	<u>12/31/2020</u>
<u>Parent</u>			
Oncoclínicas	RT Portugal	5,726	5,771
Oncoclínicas	Pontus	10,783	4,999
Oncoclínicas	CPO SP	1,444	1,444
Oncoclínicas	Multihemo	227	278
Oncoclínicas	RT Recife	-	450
Oncoclínicas	Other	463	463
Total		<u>18,643</u>	<u>13,405</u>
<u>Subsidiaries</u>			
Salvador	Multihemo	-	15
CMI	Multihemo	675	829
NOB	Noncontrolling interest (acquisition of treasury shares)	-	116

Lender	Disposal of equity interest	09/30/2021	12/31/2020
Oncopar	Pro Onco	909	851
CTO RJ	IRA	150	-
Total		1,734	1,811
Total consolidated		20,377	15,216

- (d) Includes amounts arising from events indemnifiable by the sellers of Hospital Vila da Serra, in the amount of R\$ 14,661, as mentioned in note 4 and adjusted as at September 30, 2021 with recognition of an additional amount of R\$451.

In September 2021, as a result of the acquisition of CEBROM, buyer Centro de Tratamento Oncológico S.A 9 (“CTO RJ”) recognized the amount of R\$12,518 relating to possible losses concerning tax and labor matters. Additionally, the purchase and sale agreement contains indemnification clauses and, therefore, the lawsuits were recognized as indemnifications asset and contingent liabilities.

- (e) On July 6, 2021, the purchase and sale agreement of UMC mentioned in note 1 was entered into and, in conformity with the expected clauses, buyer Multihemo made a down payment in the amount of R\$40,000 within the period agreement upon among the parties.

## 11. INVESTMENTS IN SUBSIDIARIES

### a) Breakdown

	Parent	
	09/30/2021	12/31/2020
Investments in subsidiaries	530,736	637,698
Goodwill (i)	101,195	128,068
	631,931	765,766

- (i) Refers to the goodwill arising on business combinations carried out by the Parent. The reduction during the nine months of 2021, in the amount of R\$26,873, is due to the corporate restructuring carried out in the Group, in which the Parent spun off to Idengene the goodwill of Boston Lighthouse in the amount of R\$35,611; R\$2,147 of this amount refer to the effect of foreign exchange fluctuation to the transaction date and the goodwill of Locus in the amount of R\$3,190.

With the new structure, the Parent directly controls Idengene, assuming its goodwill in the amount of R\$9,781, net of the recognition of deferred income tax and social contribution in the amount of R\$5,039, as disclosed in note 27(i).

Variations in investments are as follows:

Oncoclínicas do Brasil Serviços Médicos S.A.

Companies	12/31/2020	Profit distribution	Share of profit (loss) of subsidiaries	Changes in equity interest (ii)	Corporate restructuring (iii)	Transfer (iv)	Foreign exchange fluctuation	Capital increase (v)	Other (i)	09/30/2021
Chemotherapy	110,601	(5,065)	29,131	(6,935)	(5,969)	(63,101)	-	-	132	58,794
Radiotherapy	13,942	(420)	967	171	-	-	-	-	-	14,660
Precision medicine	8,449	-	(21,546)	-	84,604	-	(1,243)	18,197	-	88,461
Vehicle entities	475,067	(13,621)	19,152	(239,348)	(44,256)	63,101	-	73,982	(2,051)	332,026
Other	27,836	-	(11,524)	-	-	-	-	-	-	16,312
<b>Total</b>	<b>635,895</b>	<b>(19,106)</b>	<b>16,180</b>	<b>(246,112)</b>	<b>34,379</b>	<b>-</b>	<b>(1,243)</b>	<b>92,179</b>	<b>(1,919)</b>	<b>510,253</b>
Investments	637,698									530,736
Equity deficit*	(1,803)									(20,483)

\*Recorded in "Other noncurrent liabilities" in the balance sheet.

Companies	12/31/2019	Profit distribution	Share of profit (loss) of subsidiaries	Changes in equity interest (ii)	New acquisitions	Foreign exchange fluctuation	Capital increase	Other (i)	09/30/2020
Chemotherapy	124,618	(22,237)	27,992	4,358	-	-	-	-	134,731
Radiotherapy	27,067	(700)	(1,174)	(6,020)	-	-	-	120	19,293
Precision medicine	14,619	-	(9,390)	-	2,129	5,437	-	4	12,799
Vehicle entities	373,868	(16,485)	25,360	(7,729)	-	-	94,381	6,039	475,433
Other	(1,527)	-	(10,986)	-	-	-	43,475	-	30,962
<b>Total</b>	<b>538,645</b>	<b>(39,422)</b>	<b>31,802</b>	<b>(9,391)</b>	<b>2,129</b>	<b>5,437</b>	<b>137,856</b>	<b>6,163</b>	<b>673,219</b>
Investments	540,857								677,393
Equity deficit*	(2,212)								(4,174)

\*Recorded in "Other noncurrent liabilities" in the balance sheet.

#### (i) Other

##### Price change

##### In 2020

In May 2020, the Parent recognized an increase in the investment of its subsidiary Oncocentro Imagem, in the amount of R\$5,407, arising from the fair value review of the shares paid in by the remaining shareholders of Núcleo de Hematologia e Transplante de Medula Óssea de Minas Gerais Ltda.

##### In 2021

In May 2021, Oncocentro Imagem paid in a capital reserve, approved in May 2019, at Oncoclínicas Minas Gerais. The amount was contributed only by it and there was no dilution of the noncontrolling shareholders. Therefore, a negative effect on equity was recognized under "transactions between shareholders" in the amount of R\$2,051, which corresponds to the amount paid in excess of the interest.

#### (ii) Changes in equity interest

##### In 2020

In April 2020, the sale of 50% of the common shares in Centro de Excelência de Radioterapia Rio de Janeiro (RT Portugal) was carried out, reducing the Parent's investment by R\$6,020.

Pursuant to the Purchase and Sale Agreement entered into on June 1, 2020 among Oncoclínicas do Brasil and the shareholders of Oncoclínica – Centro de Tratamento Oncológico S.A, a 4.96% stake was acquired and, as from said date, the Company started to hold 100% stake in such subsidiary. The amount recognized on that date and considered for purposes of investment increase was R\$4,358.

In June 2020, the sale of 49.99% interest in Pontus was carried out; the amount of investment decrease was R\$8,744. Additionally to the purchase and sale agreement of Pro Onco in 2019, the Group acquired 80% and, at the same time, 5% was sold to a noncontrolling shareholder. The measured value of this transaction was R\$1,015 recognized as gain, when compared to the sales price.

#### In 2021

In the first nine months of 2021, share purchase and sale agreements were signed, under which the Company increased its direct and/or indirect interests in certain subsidiaries.

The amounts involved and the accounting consequences arising from purchases of noncontrolling interest are as follows:

Subsidiaries	% equity interest acquired	Price on acquisition	Carrying	Gain/loss on acquisitions accounted for in equity
		(a)	(b)	(c)
Núcleo de Oncologia da Bahia S.A.	1.00%	743	225	518
Multihemo Serviços Médicos S.A.	25.62%	80,817	15,019	65,798
CPO - Centro Paraibano de Oncologia S.A.	25.00%	29,914	2,416	27,499
Núcleo de Oncologia de Sergipe S.A.	56.79%	40,750	5,415	35,335
Hematológica - Clínica de Hematologia S.A.	41.99%	64,898	3,855	61,043
Radioterapia Oncoclínicas Recife S.A.	2.40%	132	171	(39)
CECON - Centro Capixaba de Oncologia S.A.	13.50%	6,804	928	5,876
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	24.04%	13,997	1,919	12,078
Instituto de Hematologia e Oncologia de Curitiba S.A. – Clínica Médica	6.00%	4,336	491	3,845
Aliança Instituto de Oncologia S.A.	25.00%	40,250	6,090	34,160
<b>TOTAL</b>		<b>282,640</b>	<b>36,528</b>	<b>246,112</b>

a) Refers to the amount of consideration transferred for acquisition of additional interest from noncontrolling shareholders.

b) Refers to the carrying amount of noncontrolling interests represented by the percentage of interest acquired, multiplied by the equity amount acquired on the transaction date.

c) Refers to the goodwill paid on acquisitions of noncontrolling interests, represented by the difference between the consideration transferred and the carrying amount of the investment acquired, recorded in equity under "transactions between shareholders".

## (iii) Corporate restructuring

As mentioned in Note 1, in May 2021, the Group carried out a corporate restructuring between the Parent and certain subsidiaries, consisting of the spin-off of certain balances of investments and intangibles with a contra entry to capital increase in subsidiary Idengene.

As it is a transaction between subsidiaries of the Group, the aforementioned corporate restructuring had no effect on the consolidated interim financial information of the Group, except for the recognition of the tax benefit related to deferred income tax and social contribution arising from the realization of goodwill on business combination, in the amount of approximately R\$5,000.

In the Company's individual interim financial information, the effects were as follows:

<b>Spin-offs and capital increase of Idengene</b>	<b>Amount</b>
Goodwill Boston Lighthouse "BLI"	35,611
Goodwill Locus Anat. Patol. e Citologia Ltda	3,190
Advance for future capital increase Locus Anat. Patol. e Citologia Ltda	<u>5,400</u>
<b>Subtotal (1)</b>	<b>44,201</b>
<b>Capital reduction and recognition of deferred IR and CSLL</b>	
Capital reduction at Oncohematologia Participações Ltda.	(14,819)
Recognition of deferred IR and CSLL at Idengene Medicina Diagnostica S.A.	<u>4,997</u>
<b>Subtotal (2)</b>	<b>(9,822)</b>
<b>TOTAL</b>	<b>34,379</b>

(1) The amount of R\$44,201 represents the portion of the goodwill and advance for future capital increase spun off to Idengene. The portion of the investment referring to the interest in the equity of the spun-off investees did not result in an accounting impact on the parent.

(2) The amount of R\$9,822 represents the net effect of the spin-off of the goodwill in Oncohematology and the recognition of deferred IR and CSLL on the goodwill incorporated by Idengene.

## (iv) Transfer of interest between subsidiaries

In June 2021, Centro de Tratamento Oncológico (CTO RJ) joined the corporate structure of the companies Onco Imagem, Oncologia Participação Ltda., Oncoclínicas Participação SP, Oncopar and CMI. This change had no effect on the parent's investment balance.

## (v) Capital increase

In 2021

In February 2021, the Parent spun off to Idengene Medicina Diagnóstica S.A. the amount of R\$15,905 referring to intangible assets recorded in software development.

In July 2021, in addition to the transaction above, the amount of R\$2,312 referring to intangible assets was spun off to Idengene.

The remaining amount of R\$73,982 refers to the capital increase in subsidiaries.

Dividends from subsidiaries

Dividends paid by direct subsidiaries are broken down as follows:

	Allocation of dividends		
	Parent	Noncontrolling shareholders	Total
	<u>09/30/2021</u>	<u>09/30/2021</u>	<u>09/30/2021</u>
Centro Mineiro de Infusão S.A.	1,529	1,071	2,600
Centro Paulista de Oncologia S.A.	4,975	25	5,000
Oncopar Sul Empreendimentos e Participações Ltda.	1,801	99	1,900
Oncoclínicas Participações SP Ltda.	6,111	4,739	10,850
Instituto de Oncologia de Ribeirão Preto S.A.	90	1,910	2,000
Oncocentro Imagem Serviços Médicos Ltda.	4,179	421	4,600
CPO - Centro Paraibano de Oncologia S.A.	420	2,580	3,000
	<u>19,106</u>	<u>10,844</u>	<u>29,590</u>
Total	<u>19,106</u>	<u>10,844</u>	<u>29,590</u>

Equity interest held in direct investees							
September 30, 2021							
Company	Equity interest	Total assets	Total liabilities	Equity	Profit or loss for the nine-month period	Investment amount	Profit or loss under the equity method – of direct investees
Centro Mineiro de Infusões	58.80%	170,841	136,619	34,222	13,341	20,122	10,344
Oncoclínicas Salvador	100.00%	13,468	4,379	9,089	1,251	9,089	1,251
Centro Paulista de Oncologia	99.50%	412,689	374,937	37,752	10,950	37,563	10,895
Oncopar	94.81%	102,496	11,151	91,345	5,208	86,605	4,982
Onco Participações	92.13%	82,644	221	82,423	1,123	75,936	1,067
Radioterapia Oncoclínicas Recife	7.00%	50,110	40,258	9,852	(2,785)	690	(194)
Centro Exc.ª. Radioterapia Rio de Janeiro	50.00%	12,274	1,797	10,477	(1,821)	5,239	(911)
Onco Part. SP	45.78%	80,106	0	80,106	3,967	36,673	3,635
Oncobio	60.00%	89,032	46,995	42,037	(18,289)	25,222	(10,974)
Instituto Onc. De Ribeirão Preto	4.50%	10,188	4,791	5,397	2,842	243	128
Oncocentro Imagem	90.85%	160,007	68,512	91,495	6,130	83,124	5,999
CPO - Centro Paraibano de Oncologia S.A.	14.00%	23,381	13,920	9,461	4,759	1,325	666
Idengene	99.17%	120,982	31,765	89,217	(21,150)	88,476	(19,037)
Leste Fluminense	33.49%	109,796	42,880	66,916	14,425	26,911	5,976
Boston Lighthouse	90.28%	5,069	5,443	(374)	(9,614)	-	(1,574)
Onco Part.ES RJ	99.99%	52,161	29,233	22,928	5,898	22,928	5,899
Cruz Participações	28.58%	50,014	15,594	34,420	(571)	9,837	(163)
CGS Faria Lima	99.99%	2,095	1,342	753	(551)	753	(551)
<b>Total investment</b>		<b>1,547,353</b>	<b>829,837</b>	<b>717,516</b>	<b>15,113</b>	<b>530,736</b>	<b>17,438</b>
Company	Equity interest	Total assets	Total liabilities	Equity	Profit or loss for the nine-month period	Investment amount	Profit or loss under the equity method – of direct investees
Oncohematologia	99.17%	33,427	42,159	(8,732)	61	(8,659)	60
RT Oncoclínicas São Paulo	99.00%	12,299	12,733	(434)	161	(429)	160
RT Oncoclínicas Salvador	100.00%	-	5	(5)	2	(5)	2
RT Oncoclínicas Ribeirão Preto	99.00%	-	18	(18)	(7)	(18)	(7)
Pontus Participações	50.01%	20,759	40,017	(19,258)	(25,378)	(9,632)	(12,691)
Locus	100.00%	4,886	3,767	1,119	(3,748)	-	(914)
Oncoclínica – Centro de Tratamento Oncológico	100.00%	867,893	869,633	(1,740)	12,132	(1,740)	12,132
<b>Total equity deficit</b>		<b>939,264</b>	<b>968,332</b>	<b>(29,068)</b>	<b>(16,777)</b>	<b>(20,483)</b>	<b>(1,258)</b>
<b>Total direct investments</b>		<b>2,486,617</b>	<b>1,798,169</b>	<b>688,448</b>	<b>(1,644)</b>	<b>510,253</b>	<b>16,180</b>

Equity interest held in direct investees							
September 30, 2020							
Company	Equity interest	Total assets	Total liabilities	Equity	Profit or loss for the nine-month period	Investment amount	Profit or loss under the equity method – of direct investees
Centro Mineiro de Infusões	100.00%	95,938	1,608	94,330	19,951	94,330	19,951
Oncoclínicas Salvador	100.00%	16,590	3,332	13,259	(1,168)	13,259	(1,168)
Centro Paulista de Oncologia	85.90%	106,769	69,557	37,212	12,858	31,695	11,045
Oncoclínica – Centro Trat. Oncológico	100.00%	639,644	553,145	86,498	16,877	86,498	16,628
Oncopar	99.99%	98,127	22,052	76,075	6,273	76,067	6,273
Onco Participações	99.99%	80,627	(625)	81,252	1,082	81,244	1,082
Oncohematologia	99.17%	63,019	26,629	36,389	(5,167)	36,087	(5,139)
RT Oncoclínicas Recife	4.600%	54,506	46,807	7,699	(3,048)	356	(140)
Centro de Excelência RT Rio de Janeiro	50.00%	15,085	2,668	12,417	526	6,208	336
Onco Part. SP	99.00%	74,977	11,315	63,661	5,482	63,025	5,427
Instituto Onc. De Ribeirão Preto	4.50%	9,398	5,051	4,347	2,249	196	101
Oncocentro Imagem	100.00%	138,858	17,285	121,573	7,038	121,573	7,038
Centro Paraíba de Oncologia	14.00%	25,101	17,956	7,145	6,064	1,000	849
Oncobio Serviços DE Saúde AS	60.00%	97,036	44,458	52,579	(17,345)	31,547	(10,385)
Idengene	1.00%	32,781	32,585	196	(6,645)	2	(66)
Navarra	33.49%	86,203	40,765	45,438	651	15,220	218
Pontus Part. Ltda.	50.01%	49,705	37,671	12,034	(9,462)	6,018	(6,732)
Boston Lighthouse	90.28%	13,635	(4)	13,639	(8,505)	12,314	(7,678)
Locus	100.00%	3,090	2,606	484	(1,645)	484	(1,645)
Total investment		<u>1,701,088</u>	<u>934,861</u>	<u>766,227</u>	<u>25,708</u>	<u>677,393</u>	<u>35,634</u>
Company	Equity interest	Total assets	Total liabilities	Equity	Profit or loss for the nine-month period	Investment amount	Profit or loss under the equity method – of direct investees
RT Oncoclínicas Ribeirão Preto	99.00%	-	12	(12)	(12)	(12)	(12)
Central de Gestão e Saúde	99.90%	2,609	3,227	(618)	(602)	(617)	(601)
RT Oncoclínicas Salvador	100.00%	3	6	(3)	(15)	(3)	(15)
Onco Part. ES RJ	99.99%	17,757	20,630	(2,873)	(2,180)	(2,873)	(2,180)
RT Oncoclínicas São Paulo	99.00%	12,431	13,107	(676)	(1,035)	(669)	(1,024)
Total equity deficit		32,800	36,982	(4,182)	(3,844)	(4,174)	(3,832)
Total direct investments		<u>1.733.888</u>	<u>971,843</u>	<u>762,046</u>	<u>21,865</u>	<u>673,219</u>	<u>31,802</u>

## 12. PROPERTY AND EQUIPMENT

Description	Annual depreciation rates	Parent			
		September 30, 2021			December 31, 2020
		Cost	Accumulated depreciation		Balance
			depreciation	Balance	
Machinery and equipment	10%	49,923	(10,321)	39,602	50,392
Facilities	10%	559	(292)	267	306
Furniture and fixtures	10%	3,491	(1,532)	1,959	2,200
Computers and peripherals	20%	6,939	(3,466)	3,473	2,330
Leasehold improvements	10%	17,333	(6,196)	11,137	8,747
Land	-	986	-	986	986

Advance for property and equipment	-	1,232	-	1,232	-
Construction in progress	-	5,614	-	5,614	61
Total		<u>86,077</u>	<u>(21,807)</u>	<u>64,270</u>	<u>65,022</u>

Description	Annual depreciation rates	Consolidated			
		September 30, 2021		December 31, 2020	
		Cost	Accumulate d depreciation	Balance	Balance
Machinery and equipment	10%	243,049	(90,743)	152,306	130,551
Facilities	10%	10,832	(4,418)	6,414	12,187
Furniture and fixtures	10%	29,074	(13,361)	15,713	14,872
Computers and peripherals	20%	28,857	(15,002)	13,855	9,530
Leasehold improvements	10%	270,144	(81,832)	188,312	167,151
Company cars	25%	518	(518)	-	26
Land	-	2,044	-	2,044	1,564
Advance for property and equipment	-	1,514	-	1,514	-
Construction in progress	-	24,149	-	24,149	53,334
Total		<u>610,181</u>	<u>(205,874)</u>	<u>404,307</u>	<u>389,215</u>

As at September 30, 2021, and December 31, 2020, no assets were pledged as collateral. Management has not identified significant changes in the useful lives of the assets part of its property and equipment and of its subsidiaries.

Leasehold improvements are amortized during the term of the lease contract and considers the expected renewal or disposal, when Management intends to exercise such right, and pursuant to the terms and conditions of the contracts. Land and construction in progress are not depreciated or amortized.

Oncoclínicas do Brasil Serviços Médicos S.A.

Parent	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Construction in progress	Advance	Land	Total
Balance as at December 31, 2019	35,226	358	2,126	1,609	9,765	17,135	-	986	67,205
Purchases	-	-	405	680	233	8,546	-	-	9,864
Depreciation	(3,067)	(39)	(250)	(522)	(1,048)	-	-	-	(4,926)
Transfers	7,692	-	-	-	-	(7,692)	-	-	-
Balance as at September 30, 2020	39,851	319	2,281	1,767	8,950	17,989	-	986	72,143
Balance as at December 31, 2020	50,392	306	2,200	2,330	8,747	61	-	986	65,022
Purchases	112	2	42	1,888	446	2,401	1,232	-	6,123
Depreciation	(4,215)	(39)	(286)	(754)	(1,408)	-	-	-	(6,702)
Write-offs	(173)	-	-	-	-	-	-	-	(173)
Transfers	(6,514)	(2)	3	9	3,352	3,152	-	-	-
Balance as at September 30, 2021	39,602	267	1,959	3,473	11,137	5,614	1,232	986	64,270

Consolidated	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Company cars	Land	Advance	Construction in progress	Total
Balance as at December 31, 2019	100,698	8,189	10,990	6,469	145,033	142	1,441	-	42,150	315,112
New companies										
Locus	737	-	28	188	554	-	-	-	-	1,507
Hospital Marcos Moraes	10,820	-	65	208	28,318	-	-	-	13,188	52,599
Purchases	3,549	101	1,620	2,394	15,088	-	-	-	22,794	45,546
Depreciation	(10,196)	(758)	(1,171)	(1,728)	(13,784)	(59)	-	-	-	(27,695)
Write-offs	(52)	-	(131)	(36)	-	(36)	-	-	-	(255)
Transfers	18,511	(110)	(297)	(327)	-	-	-	-	(17,777)	-
Balance as at September 30, 2020	124,067	7,422	11,104	7,168	175,209	47	1,441	-	60,355	386,814
Balance as at December 31, 2020	130,551	12,187	14,872	9,530	167,151	26	1,564	-	53,334	389,215
New companies										
CEBROM	16,034	-	505	129	614	-	-	-	-	17,282
CTR	432	3	152	90	1,023	-	480	-	15	2,195
Purchases	11,993	190	1,552	7,048	1,062	32	-	1,514	16,194	39,585
Depreciation	(16,632)	(944)	(1,601)	(3,008)	(18,618)	(58)	-	-	-	(40,861)
Write-offs	(311)	-	(84)	(45)	-	-	-	-	-	(440)
Transfers	10,239	(5,022)	317	111	37,080	-	-	-	(45,394)	(2,669)
Balance as at September 30, 2021	152,306	6,414	15,713	13,855	188,312	-	2,044	1,514	24,149	404,307

### 13. INTANGIBLE ASSETS

The Company's and its subsidiaries' intangible assets are comprised of systems and applications, exclusivity right, software development, trademarks and patents, partnership agreements and goodwill deriving from expected future earnings paid on the acquisition of investments that are justified in the estimated future cash flows, pursuant to future feasibility reports prepared by external specialists. Goodwill arising on the acquisition of investments in subsidiaries is reclassified from the group of investments in the Parent's individual financial statements to intangible assets in the consolidated financial statements.

The amounts recorded in intangible assets are broken down as follows:

Description	Annual amortization rates	Parent			
		September 30, 2021		December 31, 2020	
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	12,844	(9,109)	3,735	4,076
Exclusivity right	20%	28,141	(12,479)	15,662	22,283
Software development	-	27,972	-	27,972	35,185
Goodwill	-	9,585	-	9,585	9,585
Trademarks and patents	-	269	-	269	269
Intellectual property	20%	9,360	(406)	8,954	-
<b>Total</b>		<b>88,171</b>	<b>(21,994)</b>	<b>66,177</b>	<b>71,398</b>

Description	Annual amortization rates	Consolidated			
		September 30, 2021		December 31, 2020	
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	38,861	(27,871)	10,990	11,237
Software and project development	-	83,630	-	83,630	60,503
Exclusivity right	20%	70,769	(37,937)	32,832	41,220
Goodwill on acquisition of investments	-	843,389	-	843,389	612,208
Partnership agreement	8,3%	563,202	(44,251)	518,951	482,123
Trademarks and patents	-	746	-	746	746
Intellectual property	20%	11,695	(406)	11,289	-
<b>Total</b>		<b>1,612,292</b>	<b>(110,465)</b>	<b>1,501,827</b>	<b>1,208,037</b>

As at September 30, 2021, and December 31, 2020, no rights were pledged as collateral. Management has not identified significant differences in the useful lives of the assets part of its intangible assets and of its subsidiaries.

No losses were identified and recognized related to the impairment of intangible assets as at September 30, 2021 and December 31, 2020.

	Parent						Total
	Systems and applications	Software development	Goodwill - Oncocentro	Exclusivity right	Trademarks and patents	Intellectual property	
Balance as at December 31, 2019	4,363	11,871	9,585	1,921	269	-	28,009
Purchases	803	10,645	-	21,764	-	-	33,212
Amortization	(1,479)	-	-	(2,562)	-	-	(4,041)
Balance as at September 30, 2020	3,688	22,517	9,585	21,123	269	-	57,180
Balance as at December 31, 2020	4,076	35,185	9,585	22,283	269	-	71,398
Purchases	1,295	20,177	-	-	-	-	21,472
Amortization	(1,449)	-	-	(6,621)	-	(406)	(8,476)
Corporate restructuring	-	(18,217)	-	-	-	-	(18,217)
Transfers	(187)	(9,173)	-	-	-	9,360	-
Balance as at September 30, 2021	3,735	27,972	9,585	15,662	269	8,954	66,177

	Consolidated							
	Systems and applications	Software development	Partnership agreements (i)	Goodwill on acquisition of investments (iii)	Exclusivity right (ii)	Trademarks and patents	Intellectual property	Total
Balance as at December 31, 2019	14,656	28,523	135,788	414,922	24,744	736	-	619,369
Purchases	1,136	18,329	300,000	20,559	26,229	-	-	366,253
Amortization	(4,195)	-	(11,199)	-	(9,962)	-	-	(25,356)
Foreign exchange fluctuation	-	-	-	10,627	-	-	-	10,627
Balance as at September 30, 2020	11,597	46,852	424,589	446,108	41,011	736	-	970,893
Balance as at December 31, 2020	11,237	60,503	482,123	612,208	41,220	746	-	1,208,037
New companies								
CEBROM	1,048	-	-	-	-	-	-	1,048
CTR	72	-	-	-	-	-	-	72
Purchases	2,157	32,755	49,991	234,657	3,500	-	2,333	325,392
Amortization	(3,788)	-	(13,164)	-	(11,888)	-	(406)	(29,246)
Goodwill on corporate restructuring *	-	-	-	(5,039)	-	-	-	(5,039)
Foreign exchange fluctuation	-	-	-	1,563	-	-	-	1,563
Transfers	265	(9,627)	-	-	-	-	9,362	-
Balance as at September 30, 2021	10,990	83,631	518,950	843,389	32,832	746	11,289	1,501,827

\* Refers to the effect of the recognition of deferred income tax and social contribution on goodwill realized through the corporate restructuring disclosed in note 11 (i).

## (i) Partnership agreements – main transactions for the period

2021

- a) On February 2, 2021, an Investment Agreement and Other Covenants was signed between the Company, Unimed Grande Florianópolis – Cooperativa de Trabalho Médico (“UGF”), and UGF Participações S.A. (“UGF Par”) and a subsidiary of the Company, Cruz Participações Ltda. (currently Talassa Participações S.A.) (“Talassa”), to regulate the joint investment of the Company and UGF, through UGF Par, in Talassa. The transaction involves a contribution to Talassa, with the UGF contribution comprising an intangible asset valued at R\$49,991 thousand and the Company's contribution in the amount of R\$25,000, in order to operationalize Talassa's activities. As part of the agreement, the amount of R\$25,000 referring to redeemable preferred shares will be redeemed by Unimed. The operation also involves the execution of ancillary contracts, including a partnership agreement under which the terms and conditions in which the parties will provide chemotherapy and outpatient medical services to UGF beneficiaries and other private patients are regulated; development and direct operation of activities related to medical, hospital and health care services.

2020

- a) Central Nacional da Unimed – Cooperativa Central (CNU) and Oncoclínicas do Brasil Serviços Médicos S.A (Oncoclínicas) established a strategic partnership for a 30-year term to serve together the beneficiaries of the healthcare plans operated by CNU, who have been diagnosed with oncology disorders and who seek oncology care. This partnership will cover the cities of São Paulo, Bahia and Brasília. To set up the partnership, Oncoclínicas invested amounts together with CNU, on organized way; Oncoclínicas adopted the cash contribution method and CNU used the customer portfolio, of which R\$61,600 in Yukon, R\$38,400 in Angara and R\$200,000 in Baikal. CNU's contribution to the capital of the partnerships was made based on an economic and financial valuation report, using the discounted cash flow method, based on historical facts and future market prospects.

## ii) Exclusivity right

The non-compete right recorded in Oncoclínicas Group companies refers to clauses set out in the medical service agreements, which provide for the exclusivity right of these service providers. The average term of the agreements is five years.

## (vi) Goodwill on acquisition of investments

Breakdown of the goodwill arising on the Group's acquisitions:

	Consolidated	
	09/30/2021	12/31/2020
Oncoclínicas do Brasil Serviços Médicos S.A.	110,780	137,653
Oncoclínica – Centro de Tratamento Oncológico	235,906	6,955
Centro Mineiro de Infusões	15,982	15,982
Oncocentro Imagem Serviços Médicos	82,215	82,215
Centro de Quimioterapia Oncoclínicas	388	388
Oncopar	49,415	49,415
Oncologia Participações	16,287	16,287
Oncohematologia Participações	12,276	27,096
Idengene	43,923	-
Oncoclínicas Participações SP	53,892	53,892

Pontus Participações	10,421	10,421
Amazonas Participações	57,535	57,535
Andrômeda Participações	154,369	154,369
Total	<u>843,389</u>	<u>612,208</u>

Impairment tests of goodwill deriving from expected future earnings

Oncoclínicas Group annually tests goodwill deriving from expected future earnings to identify impairment loss, the last test was conducted for the year ended December 31, 2020. The Company monitored the assumptions used and did not identify any indication of impairment or need to conduct a new test as at September 30, 2021.

There was no need to recognize an impairment of goodwill arising on the acquisition of investments for the year ended December 31, 2020.

14. RIGHT OF USE – LEASE

The Group leases properties for its operations, including buildings. The average lease term is 10 years. The Group's obligations are collateralized by the ownership of the leased assets.

14.1. Right-of-use assets - properties

	<u>Parent</u>
Balance as at 12/31/2019	<u>19,933</u>
Addition/ remeasurement	7,552
Amortization	(3,770)
Balance as at 09/30/2020	<u>23,715</u>
Balance as at 12/31/2020	<u>24,693</u>
Addition/ remeasurement	1,026
Amortization	(3,728)
Balance as at 09/30/2021	<u><u>21,991</u></u>

	Consolidated		
	Properties	Machinery and equipment	Total
Balance as at 12/31/2019	123,019	-	123,019
New company			
Hospital Marcos Moraes	5,978	-	5,978
Addition/ remeasurement	31,604	-	31,604
Amortization	(19,886)	-	(19,886)
Balance as at 09/30/2020	<u>140,715</u>	<u>-</u>	<u>140,715</u>
Balance as at 12/31/2020	209,717	10,903	220,620
New company			
Cebrom	1,644		1,644
Addition/ remeasurement	21,688	-	21,688
Amortization	(20,962)	-	(20,962)
Balance as at 09/30/2021	<u>212,087</u>	<u>10,903</u>	<u>222,990</u>

#### 14.2. Lease liabilities

Liabilities were measured at the present value of the remaining lease payments discounted based on the average incremental rate from 6.64% to 8.10% p.a. as at September 30, 2021 and 8.10% p.a. for 2020.

Due to the maturity and renewal of some lease contracts, they were remeasured at the new monthly amount, which additional amounts were classified as addition/remeasurement.

	Parent	Consolidated
Balance as at 12/31/2019	20,600	128,707
New companies		
Hospital Marcos Moraes	-	5,978
Addition/ remeasurement	7,552	31,604
Principal repayment	(3,079)	(16,506)
Payment of interest	(1,139)	(6,106)
Interest	1,348	6,948
Balance as at 09/30/2020	<u>25,282</u>	<u>150,625</u>

Balance as at 12/31/2020	26,572	232,581
New company		
Cebrom	-	1,644
Addition/ remeasurement	1,026	21,688
Principal repayment	(3,475)	(21,496)
Payment of interest	(1,347)	(7,951)
Interest	1,542	12,872
Balance as at 09/30/2021	<u>24,318</u>	<u>239,338</u>
Current	4,566	25,860
Noncurrent	19,752	213,478

As at September 30, 2021, noncurrent is broken down as follows:

	<u>Parent</u>	<u>Consolidated</u>
2021	1,631	10,623
2022	6,523	42,258
2023	6,207	41,763
2024	5,261	36,372
2025	4,503	30,985
2026 and thereafter	6,885	308,114
Total	<u>31,010</u>	<u>470,115</u>
Embedded interest	<u>(6,692)</u>	<u>(230,777)</u>
Lease liability	<u>24,318</u>	<u>239,338</u>

Although the accounting methodology used by the Company is in line with the rule set out in CPC06(R2) /IFRS16, it generates misstatements in the information to be provided due to the mismatching between cash flow and present value, given the current reality of the long-term interest rates in the Brazilian economic environment. Accordingly, the Company recalculated the depreciation and finance charge amounts for the total term of the contracts in effect as at September 30, 2021, based on a future cash flow that incorporates the expected inflation (nominal flow).

Pursuant to Circular Letter/CVM/SNC/SEP/02/2019, the Company presents the comparative balances of lease liabilities and their respective finance costs, right-of-use assets and their related depreciation expenses, considering the effect from future projected inflation on the flows of lease contracts, discounted at the nominal rate:

	Sep/ 2021	Dec/ 2021	Dec/ 2022	Dec/ 2023	Dec/ 2024	Dec/ 2025	Dec/ 2026	Dec/ 2027	Dec/ 2028	Dec/ 2029	Dec/ 2030	Jan/2031 and thereafter
IPCA	8.49%	8.49%	4.12%	3.25%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%
Lease asset:												
Flow without inflation	222,990	216,641	188,731	161,921	139,724	122,750	110,979	100,802	92,174	83,834	76,588	70,168
Flow with inflation	241,922	235,034	196,507	167,183	143,916	126,433	114,308	103,826	94,939	86,349	78,886	72,273
Lease liability:												
Flow without inflation	239,338	239,235	233,411	209,229	184,769	163,973	147,002	135,716	125,786	117,347	108,696	101,137
Flow with inflation	259,658	259,546	243,028	216,029	190,312	168,892	151,412	139,787	129,560	120,867	111,957	104,171
Finance costs:												
Flow without inflation	(12,872)	(4,049)	(15,075)	(14,304)	(12,577)	(11,013)	(9,770)	(8,953)	(8,247)	(7,620)	(7,009)	(107,450)
Flow with inflation	(13,965)	(4,393)	(15,696)	(14,769)	(12,954)	(11,343)	(10,063)	(9,222)	(8,494)	(7,849)	(7,219)	(110,674)
Depreciation expenses:												
Flow without inflation	(20,962)	(7,084)	(27,910)	(26,810)	(22,197)	(16,975)	(11,770)	(10,178)	(8,628)	(8,340)	(7,246)	(80,411)
Flow with inflation	(22,742)	(7,686)	(29,060)	(27,681)	(22,863)	(17,484)	(12,123)	(10,483)	(8,887)	(8,590)	(7,463)	(82,823)

The Company has no potential recoverable PIS/Pasep and COFINS embedded in the lease consideration.

## 15. TRADE PAYABLES

The amounts recorded as trade payables are mainly represented by balances payable to domestic suppliers of medicine, medical services and sundry suppliers. These medicines are used in chemotherapeutic procedures.

## 16. BORROWINGS AND FINANCING

Borrowings and financing are broken down as follows:

Description	Index / interest	Final maturities	Parent		Consolidated	
			09/30/2021	12/31/2020	09/30/2021	12/31/2020
Financing	IPCA + 1.51% p.a. up to IPCA +2.82% p.a. / 10.69% p.a. / swap + 3.75% p.a. up to swap + 4.75% p.a.	04/15/2030	-	-	73,856	80,268
CCB / working capital Law 4,131 (i)	CDI + 2.95% p.a. up to CDI + 6.04% p.a.	05/01/2027	307,273	377,787	1,086,287	960,302
	LIBOR + 2.2% p.a. / CDI + 1.73% p.a.	08/05/2024	-	154,454	130,099	336,620
FINEP and FINAME (ii)	TJLP + 0.5% p.a.	12/15/2031	40,105	21,966	40,105	21,966
			<u>347,378</u>	<u>554,207</u>	<u>1,330,347</u>	<u>1,399,156</u>
Current			107,352	229,613	299,513	241,876
Noncurrent			240,026	324,594	1,030,834	1,157,280

(i) The Company contracted swaps to hedge against the fluctuations of foreign currencies on the borrowing date, under the same terms and conditions of the original borrowing agreement. Swaps are disclosed in the balance sheet in line item "Derivative financial instruments", note 6. Average finance charges correspond to approximately 100% of the CDI rate + 3.20% p.a. as at December 31, 2020, which transaction was settled in advance in March 2021. As at September 30, 2021, corresponds to approximately 100% of the CDI rate + 2.67% p.a.

(ii) The Company has a financing contract with FINEP in the total amount of R\$93,462, of which R\$40,105 have already been disbursed. The balance to be disbursed on September 30, 2021 was R\$53,357.

The settlement flow of borrowings and financing is as follows:

Settlement flow	Parent	Consolidated
2021	37,352	55,252
2022	85,385	340,804
2023	64,259	365,448
2024	66,202	340,196
2025	66,202	186,173
2026 and thereafter	27,978	42,474
	<u>347,378</u>	<u>1,330,347</u>

The variations in the balances of borrowings and financing in the periods ended September 30, 2021 and 2020 are as follows:

	Parent	Consolidated
Balance as at December 31, 2019	355,440	407,006
Additions	363,003	664,074
Interest incurred	18,013	19,634

	<u>Parent</u>	<u>Consolidated</u>
Principal repayment	(177,417)	(179,044)
Foreign exchange fluctuation	-	2,113
Payment of finance charges	(11,151)	(12,973)
	<hr/>	<hr/>
Balance as at September 30, 2020	547,888	900,810
	<hr/>	<hr/>
Balance as at December 31, 2020	554,207	1,399,156
	<hr/>	<hr/>
Additions	18,060	168,181
Interest incurred	24,811	72,380
Principal repayment	(223,821)	(247,038)
Foreign exchange fluctuation	152	285
New companies		
CEBROM	-	8,350
CTR Bueno	-	2,564
Surplus or deficit *	-	967
Payment of finance charges	(26,031)	(74,498)
	<hr/>	<hr/>
Balance as at September 30, 2021	<u>347,378</u>	<u>1,330,347</u>

\*The surplus or deficit amount derives from the valuation of investments of recently acquired companies Cebrom and CTR Bueno. The Group analyzed assets and liabilities assumed based on the account balances, statements and market information. The methodology was applied considering the future amount at the transaction rate and adjusted to present value by the indices used in each contract (IPCA and CDI) of the focus report of September 24, 2021 and the most recent rate adopted by the Group.

The Company has credit lines with banks for use in working capital management, acquisition of hospital equipment for the Oncoclínicas Group's clinics, construction works in some Group's clinics and acquisition of new clinics.

Oncoclínicas Group's exposure to interest rate risks and the sensitivity analysis for borrowings and financing are disclosed in note 28.

The Group is a party to some borrowing and financing agreements containing covenants. The Company is compliant with financial and non-financial covenants. The measurement of financial indicators takes place on an annual basis and, therefore, there is no measurement of financial indicators in interim periods. Additionally, the contractual conditions disclosed in the annual financial statements for the year ended December 31, 2020 remain unchanged.

## 17. PAYROLL AND RELATED TAXES

The amounts recorded as payroll and related taxes are broken down as follows:

Description	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Salaries and wages	71	419	4,011	4,180
Social security contribution (INSS)	1,679	1,423	6,535	4,585
Severance pay fund (FGTS)	235	334	95	377
Withholding income tax (IRRF) on payroll	703	1,085	1,269	1,849
Accrued vacation, 13th salary and related taxes	14,943	8,259	48,830	29,404
Accrued profit sharing (a)	8,727	13,350	19,590	24,230
Phantom Shares Program (b)	208,000	140,911	208,000	140,911
Other	-	376	-	661
<b>Total</b>	<b>234,358</b>	<b>166,157</b>	<b>288,830</b>	<b>206,197</b>
Current	26,358	25,246	80,330	65,286
Noncurrent	208,000	140,911	208,000	140,911

(a) Oncoclínicas Group has a profit sharing program for employees, based on the profit recorded on an annual basis. The annual amount payable is set based on results and performance indicators.

(b) Phantom Shares Program

The Company launched a compensation program consisting of granting stock appreciation rights ("phantom shares").

The "Phantom Shares" plan refers to an executive compensation program through which the Company grants to participants the right to receive a premium, in case of appreciation of the shares of Oncoclínicas do Brasil Serviços Médicos S.A. between the initial reference date and a qualified liquidity event.

Even though the Company has the option of settlement through issuance and delivery of shares, as at September 30, 2021, the Company considered as an assumption the settlement of the Phantom shares through the delivery of cash to the Beneficiaries, as it has the constructive obligation of delivering these instruments in cash.

The entity remeasures the fair value of the liability at the end of each reporting period and any changes in the fair value of these obligations are recognized in profit or loss for the period.

	Options (in thousands)
Balance as at December 31, 2019	262,528
Granted during the period	13,000
Forfeited during the period	(3,819)
Balance as at September 30, 2020	271,709
Balance as at December 31, 2020	287,672
Granted during the period	39,028
Forfeited during the period	-
Balance as at September 30, 2021	326,700

The fair value of a share-based payment transaction must be measured based on the stock market prices, if available. If there is no available market value, it must be estimated using market value valuation techniques. The rights on the appreciation of shares is reassessed by Management on a quarterly basis and provisions are supplemented or reversed according to the price calculated by Management.

	<u>09/30/2021</u>	<u>12/31/2020</u>
Provision	169,306	115,270
Social security contribution (INSS)	35,657	23,629
Severance pay fund (FGTS)	890	590
Other	2,146	1,422
	<u>208,000</u>	<u>140,911</u>

In order to measure the share price, the share price established in an open market readily available for trading at the B3 was considered.

	<u>09/30/2021</u>	<u>12/31/2020</u>
Total options granted	326,700	287,672
Share fair value	13,49	10,92
Remaining average maturity (in years)	8	13

## 18. TAXES PAYABLE

The amounts recorded as taxes payable are broken down as follows:

Description	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Withholding income tax (IRRF)	518	639	2,446	3,688
Service tax (ISSQN)	644	947	28,592	25,884
Taxes on revenue (PIS and COFINS)	2,626	2,316	20,114	22,689
Federal withholding taxes	720	1,097	2,066	2,044
Taxes in installments (ii)	-	-	4,709	7,007
PERT (i)	1,633	1,633	21,255	21,381
Tax on Financial Transactions (IOF)	2,371	2,849	3,340	3,577
Other	259	404	3,225	3,149
<b>Total</b>	<b>8,771</b>	<b>9,885</b>	<b>84,476</b>	<b>89,419</b>
Current	8,771	9,885	82,005	85,442
Noncurrent	-	-	3,742	3,977

## (i) Special Tax Regularization Program (PERT)

The Special Tax Regularization Program (PERT) was established in 2017 for payment in installments of federal tax debts held by an individual or legal entity, of public or private law, within the scope of the Brazilian Federal Revenue Service and/or General Attorneys' Office of the National Treasury.

The adhesion to PERT was made through a request filed until November 14, 2017 for debts past due up to April 30, 2017.

Adhesion to the Special Tax Regularization Program (PERT)

The Company elected to adhere to the Special Tax Regularization Program (PERT), including debts such as PIS, Cofins, IRPJ, CSLL, IOF, and installment payments included or not in the Federal executable tax debts. The decision made was to include the debts managed by the Brazilian Federal Revenue Service in cash, upon the use of tax loss carryforwards, calculated by the Company in prior years, for payment of the remaining balance, pursuant to §1, art.2 of Law 13,496/17, and the debt managed by the General Attorneys' Office of the National Treasury, payable in 145 installments, pursuant to letter b, item II, art. 3 of Law 13,496/17.

## (ii) Taxes in installments are as follows:

	Consolidated	
	09/30/2021	12/31/2020
Municipal	39	39
Federal	4,670	6,968
	<b>4,709</b>	<b>7,007</b>

## 19. PAYABLES FOR ACQUISITIONS

Acquired subsidiaries	Parent	
	09/30/2021	12/31/2020
Multihemo Serviços Médicos	4	280
Locus	-	1,958
Centro Paulista de Oncologia	38,902	25,554
<b>Total</b>	<b>38,906</b>	<b>27,792</b>
Current	1,150	2,238
Noncurrent	37,756	25,554
Acquired subsidiaries	Consolidated	
	09/30/2021	12/31/2020
Núcleo de Hematologia e Transplante de Medula Óssea	-	17,957
Pro-Onco Centro de Tratamento Oncológico	8,315	10,347
Aliança	-	8,523
Multihemo	52,587	280
Locus	-	1,958
Instituto Materno Infantil de Minas Gerais	116,255	100,145
Hospital de Oncologia do Méier	22,649	37,513
Laboratório IRA	3,242	3,027
Centro Paulista de Oncologia	38,902	25,554
Centro Paraibano de Oncologia	20,367	-
Núcleo de Oncologia de Sergipe	19,519	-
Hematológica – Clínica de Hematologia	51,106	-
Cebrom – Universitário	92,476	-
Cebrom – CTR Bueno	27,777	-
<b>Total</b>	<b>453,195</b>	<b>205,304</b>
Current	152,984	109,629
Noncurrent	300,211	95,675

Payables for acquisition of companies include Purchase and Sale Agreements arising from installments payable retained. Payables for acquisitions are subject to finance charges based on 100% of the CDI and/or IPCA and IGP-M rates fluctuation.

As mentioned in note 11, during the nine-month period ended September 30, 2021, the Group acquired additional equity interest in certain subsidiaries that were previously held by noncontrolling shareholders. The agreements entered into for the purchase of additional interest in subsidiaries Multihemo, CPO – Centro Paraibano, NOS Sergipe, CPO – Centro Paulista e Hematológica contain contingent consideration clauses with valuation of variable installments based on future performance of these subsidiaries. These instruments are measured at fair value both at the transaction date and in each closing period. The fair value of contingent considerations as at September 30, 2021 is R\$64,074.

Variations in payables for acquisitions are as follows:

	<u>Parent</u>	<u>Consolidated</u>
Balance as at December 31, 2019	30,756	92,888
Additions	16,316	70,827
Interest incurred	715	5,974
Principal repayment	(14,692)	(46,671)
Payment of finance charges	(117)	(203)
Balance as at September 30, 2020	<u>32,978</u>	<u>122,815</u>
Balance as at December 31, 2020	27,792	205,304
Additions	23,285	549,145
Interest incurred	698	22,421
Principal repayment	(9,808)	(319,622)
Capitalization – Capital contribution	(2,999)	(2,999)
Payment of finance charges	(62)	(1,054)
Balance as at September 30, 2021	<u>38,906</u>	<u>453,195</u>

The capitalization – capital contribution refers to the use of the credit of the balance payable to shareholders, for the Company's capital increase, which shareholders were included in the Company's shareholding structure, as mentioned in note 22.

Balances classified in liabilities according to their maturities are as follows:

<u>Settlement flow</u>	<u>Parent</u>	<u>Consolidated</u>
2021	4	76,910
2022	1,146	77,574
2023	1,607	85,912
2024	2,179	22,371
2025	2,354	40,285
2026 and thereafter	31,616	150,143
	<u>38,906</u>	<u>453,195</u>

## 20. OTHER LIABILITIES

<u>Description</u>	<u>Parent</u>		<u>Consolidated</u>	
	<u>09/30/2021</u>	<u>12/31/2020</u>	<u>09/30/2021</u>	<u>12/31/2020</u>
Subsidiary's equity deficit (a)	20,483	1,803	-	-
Corporate right (b)	10,001	18,791	15,521	26,513
Redemption of shares (c)	-	-	22,308	66,692
CSSJ partnership (d)	-	-	17,179	24,903
Payables - Fundação Ary (e)	7,783	9,585	7,783	9,585

Royalties payable (f)	-	-	9,698	17,450
Other payables	1,392	2,540	1,706	1,169
Total	<u>39,659</u>	<u>32,719</u>	<u>74,195</u>	<u>146,312</u>
Current	17,764	20,255	34,073	96,640
Noncurrent	21,895	12,464	40,122	49,672

- a. Balance relating to the allowance for investment losses on subsidiaries by Oncoclínicas, as shown in note 11.
- b. Balance payable relating to the exclusivity right of medical services. The contra entry to the obligations assumed is recorded part of intangible assets (see note 13). Maturities occur on a monthly basis, according to the provision of services during the term of the agreement and amounts payable are not subject to adjustment. The average term of the agreements is five years.
- c. The balance of redemption of shares refers to the shareholders' agreement, whereby Oncoclínicas Group approved the redemption of all preferred shares, with subsequent cancellation of these shares and without decreasing capital, as well as the extinguishment of the class of redeemable preferred shares, by the shareholders in Navarra companies in the amount of R\$16,000, the amount as at September 30, 2021 is R\$6,739. For Cruz Participações (Talassa) the total approved is R\$25,000 and the position in September 2021 is R\$15,569. For Baikal, the approved amount is R\$100,000 and in June 2021 it has already been fully settled. Navarra and Cruz amount is adjusted on a monthly basis by the IPCA as set forth in the agreement. The total balance of Navarra will be settled in 2023 and of Cruz in 2026.
- d. Balance payable relating to the contractual right under the partnership with Casa de Saúde São Jose (CSSJ). Amounts calculated are not subject to adjustment. In 2021, the balance payable was offset against the amount receivable from the partnership in the amount of R\$7,724 of the total of R\$24,903.
- e. Balance payable to Fundação Ary Frauzino (Foundation), relating to the arrangement set out in the purchase and sale agreement concerning the equity interest in Hospital Marcos Moraes, whereby Oncoclínicas agreed to provide financial resources to the Foundation, for the implementation of research, education and health care initiatives in the oncology area, over a period of five years. Amounts are adjusted on a monthly basis by the IGP-M as set forth in the agreement. The total balance will be settled in 2025.
- f. Balance payable relating to the adjustment installments (IGPM/FGV) of the medical service partnership agreement entered into with Hospital Felício Rocho. The contra entry of the obligations assumed was recognized as part of the intangible assets. Settlement will take place in 2021 and 2022.

## 21. PROVISIONS FOR TAX, LABOR AND CIVIL RISKS

Oncoclínicas Group records provisions to cover its potential liabilities. Based on the information provided by its legal counsel, the analysis of these matters and according to the likelihood of loss on each lawsuit, a provision considered sufficient to cover probable losses was recognized, for which a cash outflow is probable.

The provisions for risks are as follows:

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Civil	-	-	15,182	15,690
Tax	7	619	11,990	2,482
Labor	1,047	33	8,866	1,893
	<u>1,054</u>	<u>652</u>	<u>36,038</u>	<u>20,066</u>

Provisions of tax nature derive mainly from challenges related to the writ of security and objection to the tax assessment notice.

Lawsuits of labor nature derive mainly from claims for review of taxes paid, review of payment of overtime.

Specifically in relation to civil provisions, during the nine-month period ended September 30, 2021, the Group carried out an assessment of the lawsuits in which the companies are involved and determined an amount of R\$14,661 relating to the lawsuits of Instituto Materno Infantil de Minas Gerais (Hospital Vila da Serra) whose triggering event precedes the acquisition of the hospital by Oncoclínicas Group. The total amount of these lawsuits is indemnifiable by the sellers of Hospital Vila da Serra to the Group, as mentioned in note 4 .

For purposes of the effect on the buyer, CTO - Centro de Tratamento Oncológico S.A, the amount of R\$282 (civil litigation) presented by the legal and tax due diligence of Cebrom's acquisition was identified up to this date as our best estimate to recognize the contingent liability, as prescribed by IFRS 3/CPC 15. Additionally, the amount of R\$12,518 (see note 4) was recorded, relating to possible losses on tax and labor lawsuits. The purchase and sale agreement contains indemnification clauses and, therefore, the lawsuits were recognized as indemnification asset and contingent liabilities.

	Parent	Consolidated
Balance as at December 31, 2019	870	2,260
Reversal of provisions	(221)	(1,248)
Recognitions	40	286
Inflation adjustment, net	7	117
Balance as at September 30, 2020	<u>696</u>	<u>1,415</u>
Balance as at December 31, 2020	652	20,066
Reversal of provisions	(59)	(868)
Recognitions	31	15,838
Inflation adjustment, net	432	1,002
Balance as at September 30, 2021	<u>1,054</u>	<u>36,038</u>

Oncoclínicas Group monitors administrative proceedings and lawsuits to which it is a party as "plaintiff" or "defendant" and, based on the opinion of its legal counsel, classifies lawsuits according

to the likelihood of loss. The jurisprudence trends and case laws are periodically analyzed and the risks related to these lawsuits are reclassified, if necessary.

Possible losses, not provided for

The Group is a party to tax, civil and labor lawsuits, assessed by Management as possible losses, based on the opinion of its legal counsel, for which no provision was recognized. The estimated amounts are broken down as follows:

	Consolidated	
	09/30/2021	12/31/2020
Civil (i)	12,249	3,752
Labor (ii)	5,454	1,827
	<u>17,703</u>	<u>5,579</u>

- (i) Lawsuits related to the indemnity alleged for property damages and pain and suffering. There is no individually relevant lawsuit.
- (ii) The main claims refer to lawsuits related mainly to overtime, 13th salary, prior notice, vacation and FTGS, among others. There is no individually relevant lawsuit.

Considering the complexity of the lawsuits, as well as the entire Brazilian legal system, the Company is unable to accurately estimate the judgment period and whether disbursement will be made in relation to these lawsuits.

As at September 30, 2021 and December 31, 2020, escrow deposits are broken down as follows:

	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Labor	-	34	2,047	2,030
Tax	7,931	7,655	9,195	8,956
	<u>7,931</u>	<u>7,689</u>	<u>11,242</u>	<u>10,986</u>

The Company made escrow deposits that are adjusted based on the Selic rate, as from the actual deposit date. The amount of R\$11,242, including legal disputes related to tax and labor matters, in which we highlight the following deposits: (i) recovery of ICMS credit on import of surgical equipment in the amount of R\$5,657 and (ii) several escrow deposits related to labor claims in progress.

## 22. EQUITY

### (a) Capital

As at September 30, 2021, the Company's capital is R\$2,207,134, fully paid in (R\$425,656 as at December 31, 2020, partially paid in), represented by 495,357,723 common shares, and 4,050,582 common shares as at December 31, 2020.

As at September 30, paid-in capital amounts to R\$2,207,134 (R\$416,066 as at December 31, 2020).

The variations in capital in 2021 are as follows:

On May 26, 2021, the Company's shareholders, gathered at the Extraordinary Shareholders' Meeting, decided to approve the split of the common shares representing the Company's capital at a ratio of 1:100, so that each common share of the Company now corresponds to 100 common shares of the Company.

In April 2021, the amount of R\$9,590, which was subscribed by the shareholders, was paid in through loans.

On July 7, 2021, the Company's shareholders, gathered at the Extraordinary Shareholders' Meeting, decided to approve, among other matters: (i) the increase of the Company's capital, in the total amount of R\$2,999 upon the issuance of 249,996 book-entry common shares, without par value, at the issuance price of R\$12.00, which were fully subscribed and paid in by the new shareholders through capitalization of credits held by these shareholders against the Company, according to the respective subscription bulletins; and (ii) repurchase, by the Company, of 28,371,574 common shares issued by the Company, proportionally, from all shareholders on said date ("Share Repurchase"), for the amount of R\$1.00232132 per share, equivalent to the book value of the shares as at March 31, 2021, for holding in treasury.

On August 6, 2021, the capital increase by the amount of R\$1,778,478 was approved, upon the issuance of 90,049,527 new common shares at the amount of R\$19.75.

Upon the amendments, the corporate table below is presented with the new number of shares.

As at September 30, 2021, the shareholding structure is as follows:

Shareholder	Voting capital	Common shares	Shares after the split
Josephina II Fundo de Investimento em Participações	48.13%	2,384,042	238,404,159
Josephina Fundo de Investimento em Participações	13.94%	690,625	69,062,467
Bruno Lemos Ferrari	2.77%	137,311	13,731,078
Clarisse Maria de Cerqueira Mathias	0.16%	8,048	804,822
Treasury shares	5.73%	283,716	28,371,574
Other noncontrolling shareholders	29.27%	1,449,836	144,983,623
	100%	4,953,578	495,357,723

#### Share issuance costs

The transaction costs, supported by the Company, incurred with the funding through public offering and distribution of shares, totaled R\$103,999 in September 2021, and were accounted for as reduction of capital separately in equity, pursuant to CVM 649/10 and CPC 08 (R1).

#### (b) Dividend distribution policy

The Company's bylaws provides for that up to 5% of profit for the year can be allocated to the recognition of the legal reserve, until the balance reaches 20% of the Company's capital. The amount necessary can be allocated, if applicable, to the reserve for risks, pursuant to art. 195 of Law 6,404/76.

Also, the Company will keep the statutory earnings reserve called "investment reserve", which will be intended to finance the development, growth and expansion of the Company's business.

The dividend distribution policy complies with the provisions in the Brazilian Corporate Law, which provides for annual distribution; the Company can also, as decided by the Board of Directors, prepare semiannual, quarterly or monthly balance sheet and declare dividends out of the earnings recognized in these balance sheets. The Board of Directors may also declare interim dividends against the existing earnings reserve based on the last annual or semiannual balance sheet. Shareholders are entitled to minimum dividend corresponding to 25% of profit for the year as set forth in the Company's bylaws. As at December 31, 2020, Oncoclínicas do Brasil S.A. recognized accumulated losses and, therefore, did not distribute dividends to its shareholders.

As at September 30, 2021, the Group recognizes a total amount of R\$17,661 as accrued dividends payable to noncontrolling shareholders (R\$18,526 as at December 31, 2020).

During the nine-month period ended September 30, 2021, dividends to noncontrolling shareholders in the amount of R\$5,795 were declared by certain subsidiaries of the Group. As at September 30, 2020, the amount was R\$10,618.

(c) Transactions between shareholders

(i) Increase and decrease of equity interests

In 2020

In April 2020, an equity interest of 50.00% in Centro de Excelência de Radioterapia Rio de Janeiro was sold under a purchase and sale agreement entered into with Unimed Rio Participações, resulting in a decrease in equity of R\$161.

In June 2020, an addendum to the purchase and sale agreement was entered into, whereby the Group purchased equity interest from the remaining shareholders represented by 4.95% of CTO RJ, and after said date, the Group became the holder of 100% of said subsidiary's capital. This transaction resulted in a decrease in equity arising from goodwill paid on the acquisition of the additional equity interest, in the amount of R\$6,639, arising from the amount overpaid on the Company's equity.

In July 2020, an equity interest of 49.99% in Pontus was sold under a purchase and sale agreement entered into with Unimed Rio Participações; concurrently Oncoclínicas made a capital increase in the company, resulting in a negative effect on equity of R\$3,745, as payment was made by the Group only.

Noncontrolling shareholders

The transactions mentioned above relating to the purchase and sale of interest between shareholders and Oncoclínicas Group in the subsidiary correspond to:

- a) Centro de Excelência de Radioterapia Rio de Janeiro resulted in an increase in noncontrolling interest of R\$6,020.
- b) Oncoclínicas – Centro de Tratamento Oncológicos resulted in a decrease in noncontrolling interest of R\$4,358.
- c) Pontus resulted in an increase in noncontrolling interest of R\$8,744.

In 2021

As mentioned in note 11, during the nine-month period ended September 30, 2021, the Group acquired additional equity interests in certain subsidiaries that were previously held by noncontrolling shareholders for R\$282,640. These transactions had an impact on equity

in the amount of R\$246,112 due to the difference between the consideration transferred and the carrying amount of the noncontrolling interest acquired, in the amount of R\$36,528.

Additionally, during the nine-month period ended September 30, 2021, the Company recognized the contingent consideration, based on future variable installments, arising from the acquisition of additional interest in subsidiary Centro Paulista de Oncologia. The effects arising from this matter, in the amount of R\$22,606, were recognized directly in equity under “transactions between shareholders”.

#### Noncontrolling shareholders

As mentioned above, the purchases of additional interests decrease the equity of noncontrolling shareholders in the amount of R\$36,528.

In September 2020, the Group acquired equity interests in Cebrom (100%) and CRT Bueno (87.56%). The equity of noncontrolling shareholders increased by R\$531.

#### (ii) Other transactions

##### In 2020

In the nine-month period ended September 30, 2020, transactions were carried out between Oncoclínicas Group companies, which are indirectly controlled by the Company, resulting in an effect in the amount of R\$7,098 on the Company’s equity attributable to controlling shareholders, and the most relevant transaction, in the amount of R\$5,407, refers to the effect of the fair value of the share exchange, as mentioned in note 11.

#### Noncontrolling shareholders

The transaction above had an effect on the equity of noncontrolling shareholders in the amount of R\$2,203.

In addition, the general shareholders' meetings of the Company's subsidiaries approved matters related to capital increases and decreases, resulting in capital decreases that corresponded to changes in equity of R\$178,942, as shown below:

- i) Capital increases in the following companies: (i) Baikal, in the amount of R\$100,000, with contribution of the customer portfolio by shareholder Central da Unimed CNU; (ii) Angara, in the amount of R\$19,200, with contribution of the customer portfolio by shareholder Central da Unimed CNU; (iii) Yukon, in the amount of R\$30,800, with contribution of the customer portfolio by shareholder Central da Unimed CNU; (iv) Oncobio, in the amount of R\$28,983 with contribution by shareholder Bioncologia; (v) CPO PB, in the amount of R\$673 with contribution of excess earnings reserve and; (vi) Aliança, in the amount of R\$1,205.
- ii) Capital decrease in Hematológica in the amount of R\$1,679 and Radiogroup of R\$240.

##### In 2021

In the nine-month period ended September 30, 2021, transactions were carried out between Oncoclínicas Group companies, resulting in an effect in the amount of R\$3,780 on equity attributable to controlling shareholders.

Noncontrolling shareholders

The transaction above had an effect on the equity of noncontrolling shareholders in the amount of R\$2,779.

Additionally, the general meeting approved matters related to capital increases and decreases, resulting in changes in the equity of noncontrolling shareholders in the amount of R\$29,729, as shown below:

- (i) Capital decrease in Radiogroup in the amount of 400.
- (ii) Capital increase through the contribution of the customer portfolio approved in the Investment Agreement and Other Covenants between the Company and Unimed Grande Florianópolis – Cooperativa de Trabalho Médico (“UGF”), with UGF contribution comprising intangible asset valued at R\$49,991 being R\$24,991 allocated to capital.
- (iii) Capital increase through advance for future capital increase of shareholder Bioncologia in the amount of R\$5,138.

## 23. REVENUES

The reconciliation of gross sales with net revenue is as follows:

Description	Parent			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Gross revenue:				
Healthcare services	137,162	136,767	43,599	46,759
Taxes on sales and other deductions:				
PIS on sales	(871)	(875)	(268)	(294)
COFINS on sales	(4,022)	(4,037)	(1,240)	(1,354)
ISS on sales	(4,065)	(4,102)	(1,305)	(1,402)
Allowance for expected credit losses and disallowances	7,993	(5,577)	310	(2,370)
	(965)	(14,591)	(2,503)	(5,420)
Net revenue	136,197	122,176	41,096	41,339

Description	Consolidated			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Gross revenue:				
Healthcare services	2,103,603	1,601,262	744,128	570,055
Taxes on sales and other deductions:				
PIS on sales	(12,585)	(9,281)	(4,226)	(2,712)
COFINS on sales	(57,956)	(42,834)	(19,352)	(12,522)
ISS on sales	(53,522)	(43,047)	(19,125)	(15,281)

Allowance for expected credit losses and disallowances	<u>(45,353)</u>	<u>(45,228)</u>	<u>(22,005)</u>	<u>(14,682)</u>
	(169,416)	(140,390)	(64,708)	(45,197)
Net revenue	<u>1,934,187</u>	<u>1,460,872</u>	<u>679,420</u>	<u>524,858</u>

Gross revenue includes unbilled revenue relating to services provided but not yet billed by healthcare operators. These services are recognized in profit or loss based on the percentage-of-completion of the service on the date of disclosure of the financial statements, with a contra entry to "Trade receivables".

The concentration of the Company's net revenue is distributed in such a way that, in the nine-month period ended September 30, 2021, only one customer concentrated a share of more than 15% of net revenue and all other customers, if analyzed individually, accounted for volumes of less than 15% of the Company's total net revenue. In addition, the two customers with the highest concentration of sales have a share of less than 32% in the Company's total net revenue.

#### 24. COST AND EXPENSES BY NATURE

	Parent			
	<u>01/01/2021 to 09/30/2021</u>	<u>01/01/2020 to 09/30/2020</u>	<u>07/01/2021 to 09/30/2021</u>	<u>07/01/2020 to 09/30/2020</u>
Healthcare costs and medicines	(86,272)	(84,724)	(29,407)	(26,512)
Personnel and related taxes	(82,811)	(71,903)	(32,175)	(28,616)
Expenses on Phantom Share	(67,089)	(380)	136,764	6,284
Outside services	(53,293)	(32,733)	(21,553)	(12,417)
Rental and common area maintenance fees	(270)	(1,032)	(22)	(467)
Infrastructure	(1,504)	(703)	(777)	(223)
Travels	(1,848)	(1,688)	(1,209)	(68)
Use and consumption	(1,582)	(926)	(566)	(357)
Communication	(2,329)	(4,417)	(704)	(558)
Depreciation and amortization	(18,907)	(12,737)	(6,285)	(4,637)
Apportionment of expenses (i)	127,271	68,357	45,350	22,739
Provisions for tax, labor and civil risks	(402)	174	(431)	55
Other income (expenses), net	(7,075)	(6,289)	(2,238)	3,740
	<u>(196,111)</u>	<u>(149,001)</u>	<u>86,747</u>	<u>(41,037)</u>
				Parent
Cost of services	(91,238)	(88,790)	(31,108)	(30,578)
General and administrative expenses	(105,527)	(63,481)	117,599	(11,391)
Other operating income (expenses)	654	3,270	256	933
Total	<u>(196,111)</u>	<u>(149,001)</u>	<u>86,747</u>	<u>(41,037)</u>

	Consolidado			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Healthcare costs and medicines	(1,192,854)	(953,474)	(384,831)	(296,511)
Personnel and related taxes	(281,940)	(211,934)	(131,918)	(111,690)
Expenses on Phantom Share	(67,089)	(380)	136,764	6,284
Outside services	(113,133)	(67,317)	(41,253)	(26,437)
Rental and common area maintenance fees	(14,239)	(13,172)	(3,314)	(4,501)
Infrastructure	(19,164)	(8,193)	(9,422)	(2,903)
Travels	(4,057)	(2,778)	(2,666)	(260)
Use and consumption	(10,344)	(7,460)	(3,633)	(2,598)
Communication	(5,157)	(7,727)	(1,495)	(1,727)
Depreciation and amortization	(91,069)	(72,937)	(27,184)	(25,960)
Write-off of property and equipment	(440)	-	(440)	-
Provisions for tax, labor and civil risks	(2,722)	845	(2,416)	589
Other income (expenses), net	(27,882)	(30,162)	(11,250)	(4,061)
	<u>(1,830,090)</u>	<u>(1,374,689)</u>	<u>(483,058)</u>	<u>(469,775)</u>
				Consolidado
Cost of services	(1,331,008)	(1,013,633)	(460,520)	(356,661)
General and administrative expenses	(493,518)	(354,740)	(18,408)	(112,286)
Other operating income (expenses)	(5,564)	(6,316)	(4,130)	(828)
Total	<u>(1,830,090)</u>	<u>(1,374,689)</u>	<u>(483,058)</u>	<u>(469,775)</u>

- (i) Apportionment: refers to the apportionment of costs and expenses of Oncoclínicas Group's shared center, centralized in the Parent and apportioned between its subsidiaries, according to criteria defined by Management.

## 25. FINANCE INCOME (COSTS)

	Parent			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Finance income:				
Income from short-term investments	11,100	3,765	9,916	760
Discounts obtained	69	147	57	85
Interest receivable on intragroup loans	2,685	7,532	593	1,563
Derivative liabilities (swap)	4,994	4,341	1,166	4,341
Exchange gains	683	-	122	-
PIS and COFINS on finance income	(910)	(559)	(505)	(125)
Other finance income	5,723	588	307	288
	<u>24,344</u>	<u>15,814</u>	<u>11,656</u>	<u>6,912</u>

	Parent			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Finance costs:				
Interest expense on borrowings	(24,811)	(18,013)	(8,152)	(7,324)
Interest expense on debentures	-	(11,534)	-	(3,146)
Tax on Financial Transactions (IOF)	(2,071)	(253)	(430)	(57)
Interest expense on acquisitions	(698)	(715)	(655)	(228)
Bank fees	(132)	(173)	(47)	(48)
Exchange losses	(358)	-	(165)	-
Discounts granted	(7)	(91)	(3)	(4)
Interest payable on intragroup borrowings	(6,512)	(410)	(2,128)	(250)
Derivative liabilities (swap)	(1,166)	(2,597)	(1,166)	(2,597)
Interest on lease liabilities	(1,542)	(1,348)	(452)	(516)
Other finance costs	(5,505)	(2,968)	(598)	(1,187)
	<u>(42,802)</u>	<u>(38,102)</u>	<u>(13,796)</u>	<u>(15,357)</u>
Finance income (costs)	<u>(18,458)</u>	<u>(22,288)</u>	<u>(2,140)</u>	<u>(8,445)</u>

	Consolidated			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
<b>Finance income:</b>				
Income from short-term investments	23,572	8,707	15,511	2,374
Discounts obtained	581	747	233	479
Interest receivable on intragroup loans	2,007	218	681	-
Derivative liabilities (swap)	4,994	4,341	1,166	4,341
Exchange gains	1,273	389	122	295
PIS and COFINS on finance income	(2,261)	(773)	(1,064)	(153)
Other finance income	6,191	1,513	1,469	468
	<u>36,357</u>	<u>15,142</u>	<u>18,118</u>	<u>7,804</u>
<b>Finance costs:</b>				
Interest expense on borrowings	(72,380)	(19,634)	(28,867)	(7,762)
Interest expense on debentures	-	(11,534)	-	(3,147)
Tax on Financial Transactions (IOF)	(2,503)	(3,140)	(304)	-
Interest expense on acquisitions	(22,421)	(5,974)	(6,075)	(4,471)
Bank fees	(425)	(701)	(124)	(347)
Exchange losses	(1,558)	(2,113)	(658)	(381)
Discounts granted	(1,616)	(2,646)	(154)	(182)
Derivative liabilities (swap)	(1,560)	(2,597)	(1,135)	(2,597)
Interest on lease liabilities	(12,872)	(6,948)	(6,628)	(2,369)
Other finance costs	(13,393)	(4,427)	(2,762)	(1,497)
	<u>(128,728)</u>	<u>(59,714)</u>	<u>(46,707)</u>	<u>(22,753)</u>
Finance income (costs)	<u>(92,371)</u>	<u>(44,572)</u>	<u>(28,589)</u>	<u>(14,949)</u>

## 26. EARNINGS (LOSS) PER SHARE

Basic and diluted earnings (loss) per share are calculated by dividing profit or loss attributable to the Company's shareholders by the weighted average number of common shares issued in the period, excluding common shares bought by the Company and held in treasury. No dilution factors for common shares were identified, therefore, the amount of basic earnings (loss) per share will be equal to the amount of diluted earnings (loss) per share.

In compliance with CPC 41 (IAS 33) - Earnings per Share, on May 26, 2021, at an Extraordinary General Meeting the Company decided on the split of the shares at the ratio of 1:100. As the event precedes the date of issuance of the financial statements, the Company retrospectively applied the change to the calculation of basic and diluted earnings per share for all periods presented.

	<u>09/30/2021</u>	<u>09/30/2020</u>
Loss attributable to shareholders	(62,192)	(17,005)
Weighted average number of outstanding shares	411,616,174	401,724,500
Basic and diluted loss per share – in Brazilian reais (R\$)	<u>(0.1511)</u>	<u>(0.0423)</u>

## 27. INCOME TAX AND SOCIAL CONTRIBUTION

The Company and most of its subsidiaries elect for the taxable income regime, the other subsidiaries elect for the deemed income regime.

Income tax charges are as follows:

	<u>Consolidated</u>			
	<u>01/01/2021</u> to <u>09/30/2021</u>	<u>01/01/2020</u> to <u>09/30/2020</u>	<u>07/01/2021</u> to <u>09/30/2021</u>	<u>07/01/2020</u> to <u>09/30/2020</u>
Companies electing for the deemed income (a)	10,070	7,432	3,699	3,930
Companies electing for the taxable income (b)	<u>46,802</u>	<u>35,868</u>	<u>13,286</u>	<u>13,850</u>
	<u>56,872</u>	<u>43,300</u>	<u>16,985</u>	<u>17,780</u>

### (a) Income tax charges – Companies subject to deemed income regime:

	<u>Consolidated</u>			
	<u>01/01/2021 to</u> <u>09/30/2021</u>	<u>01/01/2020 to</u> <u>09/30/2020</u>	<u>07/01/2021 to</u> <u>09/30/2021</u>	<u>07/01/2020 to</u> <u>09/30/2020</u>
Revenues				
Services	318,047	220,716	111,384	107,332
Research services	33	-	-	-
Total	<u>318,080</u>	<u>220,716</u>	<u>111,384</u>	<u>107,332</u>
Deemed income tax - 8%	25,444	17,657	8,911	8,587
Deemed income tax - 32%	11	-	-	-
Deemed social contribution - 12%	38,166	26,486	13,366	12,880
Deemed social contribution - 32%	11	-	-	-
Other revenues	1,511	898	867	623
Income tax	4,045	2,783	1,467	1,381
Social contribution	3,572	2,465	1,281	1,215
Surtax (10% on excess amount)	<u>2,453</u>	<u>2,184</u>	<u>951</u>	<u>1,334</u>
Income tax and social contribution expenses	<u>10,070</u>	<u>7,432</u>	<u>3,699</u>	<u>3,930</u>

(b) Income tax charges – Companies subject to taxable income regime:

	Parent			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Profit (loss) before income tax and social contribution	(62,192)	(17,311)	145,177	14,045
Statutory tax rate	34%	34%	34%	34%
Statutory income (expense)	21,145	5,886	(49,360)	(4,775)
Adjustments to statutory expense (income)				
Share of profit (loss) of subsidiaries	5,501	10,813	6,621	7,544
Other permanent differences, net	(878)	(23)	(1,777)	(8)
Unrecognized tax credits	(25,768)	(16,389)	44,516	(2,737)
Effective income (expense)	-	306	-	24
Effective tax rate	-	-	-	-
Current	-	-	-	-
Deferred	-	306	-	24
	Consolidated			
	01/01/2021 to 09/30/2021	01/01/2020 to 09/30/2020	07/01/2021 to 09/30/2021	07/01/2020 to 09/30/2020
Profit (loss) before income tax and social contribution	11,726	41,611	167,773	40,134
Statutory tax rate	34%	34%	34%	34%
Statutory income (expense)	(3,987)	(14,148)	(57,043)	(13,646)
Adjustments to statutory expense (income)				
Other permanent differences, net	(841)	3,231	(1,549)	2,954
Effect of taxation of subsidiaries under the deemed income regime	(5,421)	7,432	(2,877)	8,417
Unrecognized tax credits	(46,623)	(39,815)	44,484	(15,505)
Effective income (expense)	(56,872)	(43,300)	(16,985)	(17,780)
Effective tax rate	485,03%	104,06%	10,12%	44,30%
Current	(62,633)	(52,080)	(19,493)	(17,711)
Deferred	5,761	8,780	2,508	(69)

(c) Deferred income tax assets - consolidated

Deferred taxes derived from temporary additions and deductions are broken down as follows:

	09/30/2021	12/31/2020
Tax benefit - goodwill arising from the downstream merger (i)	10,597	7,464
Allowance for expected credit losses and disallowance	17,783	10,244
Accrued profit sharing	2,509	2,563

Accrued trade payables and provision for risks	476	945
Accrued bonus	7,282	7,673
Surplus and deficit – Hospital Marcos Moraes	1,367	1,367
Leases	3,465	2,526
	43,479	32,782

## (i) Income tax and social contribution

## Downstream merger - Onco Salvador

The General Extraordinary Meeting held on October 31, 2017 approved the partial spin-off of Onco Salvador, which spun-off portion was merged into Mutihemo and NOB. As a result of this transaction, the goodwill recognized in Onco Salvador, arising from the difference between the carrying amount and the amount paid for the acquisition of shares by NOB and Multihemo, was transferred to NOB and Multihemo. Accordingly, NOB and Multihemo were eligible to the tax deductibility of goodwill amortization. In these companies, the amount was recognized as deferred income tax and social contribution in assets, with a contra entry to equity in line item 'Special goodwill reserve'.

## Oncohematologia and Idengene spin-off

In May 2021, with the corporate restructuring carried out by the Group mentioned in note 1, Oncohematologia spun-off to Idengene the net assets equivalent to the equity interest held in Idengene Medicina Diagnóstica S.A. The amount of R\$5,039 was recorded at Idengene and recognized in assets as deferred income tax and social contribution, with a corresponding entry to equity in the special goodwill reserve account, benefiting from the tax deductibility of goodwill amortization.

## (ii) Temporary additions/deductions

Oncoclínicas Group recognizes deferred income tax and social contribution on temporary taxable differences calculated at the end of each reporting period, between asset and liability balances recognized and the corresponding tax basis used to determine taxable income. The realization of deferred taxes, relating to temporary differences, is contingent on future events, which will make the provisions that gave rise to them to be deductible. The realization of the nature of deferred tax on tax losses is subject to the offsetting of the balances, pursuant to the tax legislation in force.

The recognized tax credits are expected to be realized as shown in the following table:

Expected realization	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
2021	639	639	16,329	23,702
2022	-	-	15,990	2,445
2023	-	-	2,361	4,866
2024 and thereafter	-	-	8,799	1,769
	639	639	43,479	32,782

## (d) Deferred income tax liabilities

Refers to the balances of deferred income tax and social contribution differences of subsidiaries subject to the deemed income taxation regime, which payment is being made on a cash basis and the related liabilities are recognized on an accrual basis.

## 28. FINANCIAL INSTRUMENTS

## (a) Financial risk factors

Oncoclínicas Group is exposed to the following financial risks: credit risk, liquidity risk and market risk. The Group's Management has the overall responsibility for setting and overseeing the risk management framework.

The risk management framework of Oncoclínicas Group was established to identify and analyze the risks to which Oncoclínicas Group is exposed, to define appropriate risk limits and controls and to monitor risks and compliance with limits imposed. Oncoclínicas Group, through training and management procedures, seeks to develop a regulatory and control environment where all employees are aware of their duties and obligations.

## (i) Credit risk

Credit risk is the risk of Oncoclínicas Group incurring losses arising from a customer or counterparty in a financial instrument and the failure of the customer or counterparty to perform contractual obligations. The risk basically derives from balances in financial institutions (current account, short-term investments and derivative instruments), trade receivables, receivables for the disposal of equity interests.

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum credit risk exposure at the end of the year is as follows:

	Note	Parent		Consolidated	
		09/30/2021	12/31/2020	09/30/2021	12/31/2020
Cash and cash equivalents	5	1,307,300	82,553	1,773,521	740,829
Securities and financial assets	6	489	46,556	33,659	79,001
Derivative assets - swap	6	-	2,549	-	2,549
Trade receivables	7	33,911	25,004	645,284	496,690
Escrow deposits	21	7,931	7,689	11,242	10,986
Disposal of equity interests	10	18,643	13,405	20,377	15,216
Related parties	29	82,534	63,183	28,317	18,630
Total		<u>1,450,808</u>	<u>240,939</u>	<u>2,512,400</u>	<u>1,363,901</u>

Cash and cash equivalents, securities and derivative financial instruments

Balances held in current accounts, short-term investments, securities and derivative financial instruments represent the maximum exposure to the credit risk of these balances. These balances are held at prime banks and financial institutions.

Trade receivables

Oncoclínicas Group's exposure to the credit risk is influenced mainly by the individual

characteristics of each customer/health insurance plan. However, Management considers the history of each customer in its analysis, based on the default risk.

The management of this risk mainly involves the A curve health insurance plans aiming at ensuring the full receipt of the revenue arising therefrom. The risk is mitigated by the widespread customer portfolio and the possibility of discontinuance of services to the beneficiaries of health insurance plans after a given default period.

#### Impairment losses

	Note	Consolidated	
		09/30/2021	12/31/2020
Trade receivables	7	705,896	565,810
Allowance for expected losses and disallowances	7	(60,612)	(69,120)
		<u>645,284</u>	<u>496,960</u>
% of the allowance on the balance of trade receivables		<u>8.59%</u>	<u>12.22%</u>

As at September 30, 2021 and December 31, 2020, the allowance for expected credit losses refers mainly to disallowances identified by health insurance plans during the year, and the low expectation of receipt according to the receivable expired period.

The assessment of the amount of past-due trade receivables not subject to impairment is constantly monitored by the sales managers of each healthcare center, to identify amounts that may not be collected. In this case, an allowance will be recognized at the amounts of the respective expected losses.

#### Receivables for the disposal of equity interests

Balances arising from receivables for disposal of equity interests represent the maximum exposure to the credit risk of these balances.

#### (ii) Liquidity risk

Liquidity risk is the risk of the Group not having sufficient resources to honor its financial commitments as a result of the mismatch of term or volume between expected receipts and payments. Oncoclínicas Group's approach in managing liquidity is to ensure, to the extent possible, sufficient liquidity to comply with its obligations when they fall due, under normal and stress conditions, without causing unacceptable losses or jeopardizing Oncoclínicas Group's reputation.

The table below analyzes Oncoclínicas Group's non-derivative financial liabilities and derivative financial liabilities that are settled on a net basis by Oncoclínicas Group, by maturity ranges, which correspond to the remaining period between the balance sheet date and the contractual maturity date. The derivative financial liabilities are included in the analysis if their contractual maturities are essential to obtain an understanding of the cash flows. The amounts disclosed in the table are the contracted undiscounted cash flows.

			Parent						
			Future payment flow						
	Note	Accounting position in September 2021	Total future flow	2021	2022	2023	2024	2025	2026 and thereafter
Trade payables	15	35,132	35,132	35,132	-	-	-	-	-
Borrowings and financing	16	347,378	402,924	42,036	106,111	77,435	74,814	70,383	32,145
Payables for acquisitions	19	38,906	54,401	4	1,146	1,607	2,179	2,354	47,111
Fundação Ary partnership	20	7,783	8,589	1,115	3,954	1,862	1,078	580	-
Exclusivity right	20	10,001	10,001	6,287	3,349	365	-	-	-
Related parties	29	2,912	2,912	-	-	2,912	-	-	-
<b>Total</b>		<b>442,112</b>	<b>513,959</b>	<b>84,574</b>	<b>114,560</b>	<b>84,181</b>	<b>78,071</b>	<b>73,317</b>	<b>79,256</b>

			Consolidated						
			Payment flow						
	Note	Accounting position in September 2021	Total future flow	2021	2022	2023	2024	2025	2026 and thereafter
Trade payables	15	373,607	373,607	373,607	-	-	-	-	-
Borrowings and financing	16	1,330,347	1,570,539	75,661	432,092	430,323	380,168	202,884	49,411
Payables for acquisitions	19	453,195	562,393	78,535	90,582	99,661	25,646	46,006	221,963
Redemption of shares	20	22,308	27,039	9	11,084	4,974	3,986	3,657	3,329
CSSJ partnership	20	17,179	21,439	1,855	7,825	11,759	-	-	-
Fundação Ary partnership	20	7,783	8,589	1,115	3,954	1,862	1,078	580	-
Partnership - Hospital Felício Rocho	20	9,698	10,494	-	10,494	-	-	-	-
Exclusivity right	20	15,521	15,521	11,807	3,349	365	-	-	-
Related parties	29	568	568	568	-	-	-	-	-
<b>Total</b>		<b>2,230,206</b>	<b>2,590,189</b>	<b>543,157</b>	<b>559,380</b>	<b>548,944</b>	<b>410,878</b>	<b>253,127</b>	<b>274,703</b>

### (iii) Market risk

#### Risk of cash flow or fair value associated with interest rate

Oncoclínicas Group's interest rate risk arises from long-term borrowings. Borrowings and financing subject to variable rates expose Oncoclínicas Group to cash flow interest rate risk. Borrowings and financing subject to fixed rates expose Oncoclínicas Group to fair value risk associated with the interest rate. Oncoclínicas Group monitors its exposure to benchmark interest rate fluctuation, arising from debt instruments, and conducts sensitivity tests using different rates during its financial planning to ensure liquidity even during scenarios with higher interest rate fluctuation.

#### Interest rate sensitivity analysis

The sensitivity analysis for interest on borrowings and financing used as probable scenario (Scenario I) the benchmark rates obtained at the Central Bank of Brazil's website (<https://www.bcb.gov.br>) as at September 30, 2021, and scenarios II and III take into consideration an increase in such rate by 25% and 50%, respectively. The results in nominal values are as follows:

Scenarios	Current scenario I	Current scenario II +25%	Current scenario III +50%
CDI rate (p.a.)	2.98%	3.73%	4.47%
IGPM rate (p.a.)	24.86%	31.07%	37.29%
IPCA rate (p.a.)	10.25%	12.81%	15.37%
Interest expenses (Parent)	24,811	25,736	25,921
Interest expenses (Consolidated)	72,380	75,079	75,619

The Company believes that the 25% and 50% variation, besides reflecting best market practices, also represents the reality presented in relation to the historical variation of the respective indicators in the period analyzed.

The DI rate increased by 224% in the first nine months of 2021. Even with this growth, the amounts are still within the safety margin assumed by the Company for the budget for the year. However, if these indicators continue to increase significantly, this will represent a risk for the Company.

Considering these factors, the stress of 25% and 50% is appropriate for the Company's sensitivity analysis.

Most of the Company's debt is pegged to the CDI rate (more than 90%), which floating rate risk is the main risk factor for the Company.

The Group has certain financial liabilities measured at fair value through profit or loss (derivative financial instruments of hedging swap and contingent considerations arising from acquisition of noncontrolling interest). Oncoclínicas Group does not designate derivatives as hedging instruments under a fair value hedge accounting model.

#### (iv) Currency risk

In order to reduce its borrowings costs, the Company contracted borrowings in foreign currency. As a strategy to manage the foreign exchange rate risk, Oncoclínicas Group simultaneously and necessarily carries out swap transactions under identical conditions in terms of amount, term and rate, swapping the exposure to exchange rate differences for the CDI fluctuation. Swap transactions are carried out solely for hedge purposes.

In April 2020, Oncoclínicas contracted a borrowing in the amount of US\$30,000, with principal maturity in April 2021. Simultaneously, a swap transaction was contracted to eliminate the foreign currency exposure risk, exchanging the Libor USD plus spread for the CDI fluctuation. This transaction was settled in advance in March 2021.

Also in March 2021, Centro Paulista de Oncologia S.A. contracted a borrowing in the amount of US\$24,000 with principal maturity in September 2022. Similarly, a swap transaction was contracted to eliminate the foreign currency risk, swapping the Libor USD plus spread for the CDI fluctuation.

The Company is not exposed to currency risk as it carries out swap transactions tied to this foreign currency-denominated borrowing.

The fair value of these instruments at the balance sheet date is as follows:

Description	Consolidated		Fair value - 2021
	Maturity range	Domestic notional value	
Swap:	09/19/2022		
Long position	100% LIBORUSD + 2.20%	R\$132,211	-
Short position	100% CDI-CETIP + 2.67%	R\$138,339	6,129

Description	Parent and Consolidated		Fair value - 2020
	Maturity range	Domestic notional value	
Swap:	04/19/2021		
Long position	100% LIBORUSD + 2.49%	R\$157,003	2,549
Short position	100% CDI-CETIP + 3.20%	R\$154,454	

The Company mainly operates in the domestic market and its receivables and payables are almost in full denominated in domestic currency. The Company has a risk management policy, which determines that agreements that may pose foreign exchange risk and may significantly affect the Company's financial statements, must be subject to measures to hedge and mitigate such impact by Management.

(b) Capital management

The Company's objectives when managing its capital are to safeguard Oncoclínicas Group's ability to continue to offer return to its shareholders and benefits to other stakeholders and to maintain an optimal capital structure for reducing this cost.

In order to maintain or adjust the capital structure, the Company may review the dividend payment policy, return capital to shareholders or, also, issue new shares or sell assets to reduce, for example, indebtedness level.

As at September 30, 2021 and December 31, 2020, the financial leverage ratios are summarized as follows:

	Consolidated	
	09/30/2021	12/31/2020
Total borrowings and financing (note 16)	1,330,347	1,399,156
Derivative financial instruments (note 6)	6,129	(2,549)
Less: cash and cash equivalents and securities	(1,807,180)	(819,789)
Net debt	-	576,818
Total equity	1,884,576	677,306
Total capital (equity + net debt)	<u>1,884,576</u>	<u>1,254,124</u>
Financial leverage ratio - %	0%	46%

(c) Estimate of fair value through profit or loss

Considering the nature and terms of transactions, the Company's Management believes that the carrying amounts of financial assets and financial liabilities, except for related-party balances

(whose respective nature and conditions are disclosed in note 29), as well as the balances of borrowings and financing and debentures, approximate their respective fair values.

Financial assets measured at fair value comprise derivative financial instruments, which measurement is based on observable market inputs (Level 2) and contingent consideration (Level 3), which measurement is based on present value of discounted cash flows. As disclosed in note 19.

(d) Financial instruments by category

Financial instruments	Measurement	Parent			
		Carrying amount	Fair value	Carrying amount	Fair value
		September 30, 2021	September 30, 2021	December 31, 2020	December 31, 2020
Cash and cash equivalents	Amortized cost	1,307,300	(*)	82,553	(*)
Securities and financial assets	Amortized cost	489	(*)	46,556	(*)
Derivative assets - swap	Fair value (Level 2)	-	-	2,549	2,549
Trade receivables (note 7)	Amortized cost	33,911	(*)	25,004	(*)
Escrow deposit	Amortized cost	7,931	(*)	7,689	(*)
Disposal of equity interest (note 10)	Amortized cost	18,643	(*)	13,405	(*)
Related parties	Amortized cost	82,534	(*)	63,183	(*)
		<u>1,450,808</u>		<u>240,939</u>	
<b>Financial liabilities</b>					
Trade payables	Amortized cost	35,132	(*)	46,594	(*)
Borrowings and financing	Amortized cost	347,378	399,557	554,207	555,616
Payables - Fundação Ary	Amortized cost	7,783	(*)	9,585	(*)
Payables for acquisition	Fair value (Level 3)	22,803	22,803	-	-
Payables for acquisition	Amortized cost	16,103	(*)	27,792	(*)
Exclusivity right	Amortized cost	10,001	(*)	18,791	(*)
Related parties	Amortized cost	2,912	(*)	59,091	(*)
		<u>442,112</u>		<u>716,060</u>	

		Consolidated			
	Measurement	Carrying amount	Fair value	Carrying amount	Fair value
		September 30, 2021	September 30, 2021	December 31, 2020	December 31, 2020
<b>Financial instruments</b>					
Cash and cash equivalents	Amortized cost	1,773,521	(*)	740,829	(*)
Securities and financial assets	Amortized cost	33,659	(*)	79,001	(*)
Derivative assets - swap	Fair value (Level 2)	-	-	2,549	2,549
Trade receivables (note 7)	Amortized cost	645,284	(*)	496,690	(*)
Escrow deposit	Amortized cost	11,242	(*)	10,986	(*)
Disposal of equity interest (note 10)	Amortized cost	20,377	(*)	15,216	(*)
Related parties	Amortized cost	28,317	(*)	18,630	(*)
		<u>2,512,400</u>		<u>1,363,901</u>	
<b>Financial liabilities</b>					
Trade payables	Amortized cost	373,607	(*)	345,801	(*)
Borrowings and financing	Amortized cost	1,330,347	1,498,893	1,399,156	1,411,689
Payables - Fundação Ary	Amortized cost	7,783	(*)	9,585	(*)
CSSJ partnership	Amortized cost	17,179	(*)	24,903	(*)
Partnership - Hospital Felício Rocho	Amortized cost	9,698	(*)	17,450	(*)
Redemption of shares	Amortized cost	22,308	(*)	66,692	(*)
Payables for acquisition	Fair value (Level 3)	64,074	64,074	-	-
Payables for acquisition	Amortized cost	389,121	(*)	205,304	(*)
Exclusivity right	Amortized cost	15,521	(*)	26,513	(*)
Related parties	Amortized cost	568	(*)	6,411	(*)
		<u>2,230,206</u>		<u>2,101,815</u>	

(\*) Except for the related-party balances, whose nature and conditions are disclosed in note 29, the Company's Management believes that the carrying amounts of the financial assets and financial liabilities measured at amortized cost approximate their respective fair values, considering that they are adjusted by allowances, present values and/or adjusted by floating market rates.

## 29. RELATED PARTIES

Related-party transactions were carried out according to the terms and conditions agreed upon among the parties. They are mainly comprised of receivables from shareholders, dividends receivable and payable, intragroup borrowings and loans and advances for future capital increase in investees:

- i) Transfer of funds between Group companies (intragroup loans): Management transfers funds between Group companies. Balances are partially eliminated on consolidation. These balances

are mostly adjusted by the IPCA and CDI. The remaining balance in consolidated refers to noncontrolling shareholders and has an average maturity of two years.

- ii) **Apportionment:** refer mainly to centralized shared services provided by the Parent, such as financial services (receivables and payables), accounting, legal, treasury, supplies, etc., which are shared among the other Group entities based on apportionment criteria that take into account the contribution of each entity for the Group's operations. Payments are made on a monthly basis and are not adjusted. These balances are mainly eliminated in the consolidated financial statements.
- iii) **Special Tax Regularization Program (PERT):** Management decided to use part of the tax loss carryforwards accumulated and declared by the Parent to settle the remaining balance of the consolidated debts, transferring the credits included in the program to the Group subsidiaries. The deadline for realization of the balance is the ratification of credits and debits by the Brazilian Federal Revenue Service. These balances are fully eliminated in the consolidated financial statements.

#### 29.1. Related parties (assets)

Assets	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
<u>Intragroup borrowings (i)</u>				
Related parties:				
Centro Paulista de Oncologia		-	973	974
Navarra (i.a)	2,555	13,259	-	-
Talassa	5	-	-	-
CMI	1,000	-	-	-
Oncoclínicas Canoas C. de Oncologia.	-	101	-	-
CECON	-	-	-	83
Radioterapia Oncoclínicas Recife (i.b)	7,853	7,451	-	-
Núcleo de Hematologia e Transplante	-	-	111	111
Pontus	465	-	-	-
Fundação Ary	-	-	868	-
Noncontrolling shareholders (i.c)	26,365	17,462	26,365	17,462
Total intragroup loans (A)	<u>38,243</u>	<u>38,273</u>	<u>28,317</u>	<u>18,630</u>
	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
<u>Apportionments (ii)</u>				
Nature:				
Shared Service Center	30,667	11,859	-	-
Project – units construction	5,047	4,474	-	-
Other	4,470	4,470	-	-
Total apportionments (b)	<u>40,184</u>	<u>20,803</u>	<u>-</u>	<u>-</u>

Special Tax Regularization Program (PERT) (iii)	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
Related parties:				
Oncoclínica – Centro Trat. Oncológico	2,454	2,454	-	-
NOS	107	107	-	-
Radioterapia Botafogo	267	267	-	-
Centro de Quimioterapia				
Oncoclínicas	241	241	-	-
CECON	80	80	-	-
Hematológica	958	958	-	-
Total PERT (c)	<u>4,107</u>	<u>4,107</u>	<u>-</u>	<u>-</u>
Total (a) + (b) + (c)	<u>82,534</u>	<u>63,183</u>	<u>28,317</u>	<u>18,630</u>

- i.a. Refers to intragroup loans with Navarra RJ Serviços Oncológicos S.A. (“Leste Fluminense”), which are monthly adjusted by the CDI rate. The intragroup loan agreements have a two-year term and can be settled before maturity.
- i.b. Refers to intragroup loan transactions with Radioterapia Oncoclínicas Recife S.A. (“RT Recife), which are monthly adjusted by the CDI rate + 3% p.a. The intragroup loan agreements have a four-year term and can be settled before maturity.
- i.c. Balances with noncontrolling shareholders are monthly adjusted by the CDI rate + 2.96% p.a. In August 2021, there was a renegotiation of terms and the adjustment index.

29.2. Dividends receivable - Parent

	Parent	
	09/30/2021	12/31/2020
<u>Dividends receivable</u>		
Related parties:		
Centro Mineiro de Infusões	1,598	1,598
Centro Exc.ª. Radioterapia Rio de Janeiro	-	184
Navarra	553	553
Instituto Oncológico de Ribeiro Preto	-	12
	<u>2,151</u>	<u>2,347</u>

29.3. Advance for future capital increase (assets)

	Parent	
	09/30/2021	12/31/2020
<u>Advance for future capital increase</u>		
Related parties:		
Oncopar	2,608	12,019
Centro Mineiro de Infusões	58,141	17,508
Oncologia Participações	60	-
Oncohematologia	40,953	28,286
Radioterapia Oncoclínicas São Paulo	1,584	1,584
Oncobio Serviços de Saúde	3,753	7,707
Centro Exc.ª. Radioterapia Rio de Janeiro	3	3
Copacabana	10,000	
Oncoclínicas Participações São Paulo	-	2,787
Idengene	11,753	1,251
Radioterapia Oncoclínicas Recife	-	253
Central de Gestão e Saúde Ltda	-	1,948
Oncoclínicas Rio de Janeiro S.A.	-	29,232
Pontus Participações	15,788	259
Locus	1,500	3,900
Oncologia Participações RJ ES	29,231	15,309
Navarra	5,007	10
Total	<u>180,381</u>	<u>122,056</u>

29.4. Related parties (liabilities)

Liabilities	Parent		Consolidated	
	09/30/2021	12/31/2020	09/30/2021	12/31/2020
<u>Intragroup borrowings</u>				
Other:				
Borrowing payable CPO (i.d)	-	4,095	-	-
Borrowing payable CTO RJ (i.e)	44	44,703	-	-
Capital decrease	-	6,684	-	6,411
Apportionments payable	2,868	3,609	568	-
Total (B)	<u>2,912</u>	<u>59,091</u>	<u>568</u>	<u>6,411</u>
Total (A) + (B)	<u>2,912</u>	<u>59,091</u>	<u>568</u>	<u>6,411</u>

- i.d. Refer to intragroup loan transactions with Centro Paulista de Oncologia S.A (“CPO”, which are monthly adjusted by the fluctuation of average daily DI rates + 1% p.a. The intragroup borrowing agreements have a five -year term and can be settled before maturity. Additionally, the total balance was settled in this quarter.
- i.e. Refers to intragroup loan transactions with Centro de Tratamento Oncológico S.A. (“CTO RJ”), which are monthly adjusted by the CDI rate + 4% p.a. The intragroup loan agreements have a three-year term and can be settled before maturity.

Also, the Group has entered into service agreements with companies owned by some of its directors in the amount of R\$5,952 in the first nine months of 2021 (R\$7,232 in the first nine months of 2020), the purpose of which is to provide specific medical services in one or more specialties among those developed by the professional in question, including the performance of medical consultations, diagnoses, prescription and follow-up of treatments in the Company's premises and/or partners defined by the Company.

#### 29.5. Dividends payable

	Consolidated	
	09/30/2021	12/31/2020
<u>Dividends payable</u>		
Multihemo	2,551	2,551
Núcleo de Oncologia da Bahia	495	495
Onco Vida	-	407
NOS	844	844
Centro Paulista de Oncologia	25	-
Aliança	11,547	12,396
Navarra	1,098	1,098
Angará	373	373
Yukon	141	141
Instituto Oncológico de Ribeirão Preto	-	37
Centro Exc. <sup>a</sup> . Radioterapia Rio de Janeiro	-	184
COT	587	-
Total	<u>17,661</u>	<u>18,526</u>

#### 29.6. Advance for future capital increase (liabilities)

	Consolidated	
	09/30/2021	12/31/2020
<u>Advance for future capital increase</u>		
Subsidiaries:		
Oncobio	2,432	5,074
Oncovida	2,492	3,289
Other	4	113
Total	<u>4,928</u>	<u>8,476</u>

Management compensation

Management members are the persons with authority and responsibility for planning, steering and controlling the Group's activities, including any officer (executive or otherwise).

During the nine-month period ended September 30, 2021, Management compensation amounted to R\$19,216 (R\$15,524 in September 2020) due to short-term benefits, such as wages, related taxes and others. As long-term benefits, the Company recognized an expense related to the phantom shares granting program of R\$54,323 (R\$1,506 as at September 30, 2020). Management compensation does not include amounts such as: (a) post-employment benefits (pension, other retirement benefits, post-employment life insurance, and post-employment health care); (b) long-term benefits (leave of absence for length of service and long-term disability benefits); and (c) severance benefits.

## 30. INSURANCE

The Company has insurance coverage based on the risks associated to its operations. The insurance policy is directly taken by Oncoclínicas, and insurance premiums and risks are covered for the Company as described in the policy.

The insurance risk and line are described below, and the insured amounts and coverage encompass the entire Oncoclínicas Group.

Insurance line	Coverage	Validity date
Civil liability	R\$1,000	12/14/2021
D&O administrative liability	R\$100,000	04/29/2022
E&O professional liability	R\$30,000	12/18/2021
Property	R\$35,500	12/31/2021

## 31. NON-CASH TRANSACTIONS

## a) Cash and cash equivalents

The breakdown of cash and cash equivalents included in the statements of cash flows is disclosed in note 5.

## b) Non-cash transactions

	Note	Parent		Consolidated	
		09/30/2021	09/30/2020	09/30/2021	09/30/2020
Acquisition, business combinations					
<b>Cash and cash equivalents acquired</b>	<b>4</b>	-	-	<b>(1,754)</b>	<b>(746)</b>
<u>Statement of cash flows</u>					
Amount paid on acquisitions	4	-	3,729	122,386	26,049
<b>Payment in business acquisitions, net of cash acquired</b>		-	<b>3,729</b>	<b>120,632</b>	<b>25,303</b>
<b>Variation in trade receivables</b>		<b>8,907</b>	<b>(1,636)</b>	<b>148,594</b>	<b>69,145</b>
Recognition (reversal) of allowance for expected credit losses and disallowances	23	(7,993)	5,557	45,353	45,228
<b>Non-cash effect</b>					
Receivables acquired through business combination			-	(5,547)	(823)

Offset of trade receivables - CSSJ partnership	20		-	7,724	
<b>Total effects on the statement of cash flows</b>		<b>914</b>	<b>3,761</b>	<b>196,124</b>	<b>113,550</b>
Derivative assets - swap					
Changes in derivatives – swap	6	-	18,907	-	18,907
<b>Non-cash effect</b>					
Derivatives - Swap		-	(21,504)	-	(21,504)
Total swap with effect on profit or loss		-	2,597	-	2,597
Derivative liabilities - swap					
Changes in derivatives – swap	6	-	-	(6,129)	-
<b>Non-cash effect</b>					
Derivatives - Swap		-	-	5,736	-
Total swap with effect on profit or loss		-	-	393	-
Property and equipment and intangible assets					
Variation in property and equipment		(752)	4,938	15,092	71,702
Variation in intangible assets		(5,220)	29,171	293,790	351,524
<b>Total variation in property and equipment and intangible assets</b>		<b>(5,972)</b>	<b>34,109</b>	<b>308,882</b>	<b>423,226</b>
Depreciation of property and equipment	12	6,702	4,926	40,861	27,696
Amortization of intangible assets	13	8,476	4,041	29,246	25,356
Write-off of property and equipment	12	173	-	440	225
<b>Non-cash effect</b>					
Intangible assets and exclusivity right payable		-	(18,121)	(2,500)	(19,627)
Transfer of asset (software) – corporate restructuring	11 and 13	18,217	-	-	-
Corporate restructuring – deferred income tax and social contribution on goodwill	11 and 13	-	-	5,039	-
Exchange rate fluctuation of goodwill – translation to presentation currency		-	-	(1,563)	(16,064)
Goodwill - Cebrom and CTR Bueno	4	-	-	(234,406)	-
Goodwill - Hospital Marcos Moraes	4	-	-	-	(10,337)
Goodwill - Locus		-	-	-	(3,190)
Goodwill - NHO – fair value in share exchange	11	-	-	-	(5,407)
Reclassification of imports in progress (property and equipment) to inventories	12	-	-	2,669	-
Payment of capital of the customer portfolio	22.c)	-	-	(49,991)	(250,000)
Property and equipment and intangible assets acquired through business combination	4	-	-	(20,597)	(54,106)
<b>Total effects on the statement of cash flows</b>		<b>27,596</b>	<b>24,955</b>	<b>78,078</b>	<b>177,802</b>
Statement of cash flows					
Acquisition of property and equipment	12	6,123	9,864	39,584	45,547
Acquisition of intangible assets	13	21,473	15,091	38,494	72,255
Taxes payable					
<b>Variation in taxes payable</b>		<b>(1,114)</b>	<b>1,180</b>	<b>6,057</b>	<b>15,332</b>
Tax paid		-	-	3,774	3,346
<b>Non-cash effect</b>					
Taxes acquired through business combination		-	-	(471)	(55)
Offset of credits		-	-	7,005	9,358
<b>Total effects on the statement of cash flows</b>		<b>(1,114)</b>	<b>1,180</b>	<b>16,365</b>	<b>27,981</b>
Advance for future capital increase – ASSETS					

<b>Variation in advance for future capital increase - assets</b>		<b>58,325</b>	<b>(50,008)</b>	-	<b>1,200</b>
<b><u>Non-cash effect</u></b>					
Transfer of advance for future capital increase to increase of capital in the investment	11	73,962	137,856	-	-
Other	11	5,400	-	-	(1,200)
<b>Total with cash effect of the advance for future capital increase</b>		<b>137,687</b>	<b>87,848</b>	-	-

Advance for future capital increase –  
LIABILITIES

<b>Variation in advance for future capital increase - liabilities</b>		-	-	<b>(3,458)</b>	<b>(27,165)</b>
<b><u>Non-cash effect</u></b>					
Transfer of advance for future capital increase to capital increase made by noncontrolling shareholders in equity		-	-	5,138	28,983
<b>Total with cash effect of the advance for future capital increase</b>		-	-	<b>1,590</b>	<b>1,818</b>

Contingency

Variation in contingency		-	-	15,972	-
<b><u>Non-cash effect</u></b>					
Possible losses - Cebrom indemnifiable at the buyer	23	-	-	(12,800)	-
Adjustment to indemnifiable asset - HVS	23	-	-	(451)	
<b><u>Total contingencies with effect on profit or loss</u></b>				<b>2,722</b>	

### 32. EVENTS AFTER THE REPORTING PERIOD

On October 1, 2021, the Company acquired the shareholding control of UMC and entered into an agreement for acquisition of the remaining interest of Oncobio.

On October 10, 2021, the Company has entered into a Binding Memorandum of Understanding (“MOU”) with Unimed – Rio Cooperativa de Trabalho Médico do Rio de Janeiro Ltda and Unimed Rio Empreendimentos Médicos Hospitalares Ltda, for the establishment of an integrated cancer center at Hospital Unimed (“Cancer Center”).

These transactions are further detailed in note 1.

On October 19, 2021, the Company amended the agreement for the granting of phantom shares to part of the plan beneficiaries, upon mutual agreement, whereby it has agreed to anticipate the exercise of the vested phantom shares through the delivery of treasury shares with final notional value defined. The Company also acknowledges that the Beneficiary must maintain the right to vest any and all phantom shares not vested up to this date.

### 33. APPROVAL OF INTERIM FINANCIAL INFORMATION

The Company's interim financial information for the nine-month period ended September 30, 2021 was approved and authorized for issue by the Board of Directors on November 12, 2021.